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Introduction: South Africa has a maternal ratio of 300 deaths/100,000 live births. Non-pregnancy related 
infections (mainly deaths in HIV infected pregnant women complicated by tuberculosis and pneumonia) 
accounts for 34.7% of maternal deaths followed by obstetric haemorrhage and hypertension accounts (15.8% 
and 14.8% respectively). Moreover, 61% of women South Africa is overweight or obese (almost double the 
global rate of 30%).  In pregnancy, endocrine and metabolic maternal adaptations include increase in body 
weight, however, the impact of adipokines in HIV associated pre-eclampsia remains unknown. The aim of the 
study was to examine the levels of adipokines viz., C-peptide, ghrelin, gastric inhibitory polypeptide (GIP), 
glucagon like peptide 1 (GLP), plasminogen activator inhibitory (PAI) 1, visfatin, glucagon and insulin in HIV 
associated pre-eclampsia.  
 
Materials and Methods: Following institutional and regulatory approval, participants (n=301) were recruited 
from RK Khan Hospital and divided into groups non-pregnant (n=90), normotensive (n=121), early (n=32; 
EOPE) and late onset (n=58; LOPE) pre-eclampsia. The pregnant cohort was stratified according to their HIV 
status. Maternal clinical demographics, indications and mode of delivery were recorded. Serum was used to 
quantify the adipokines levels using the multiplex ELISA technique.  Absorbance was read 
spectrophotometrically at 450 nm.  Graph Pad Prism (version 6) was used to analyse all data.  
 
Result: C-peptide did not differ according to HIV status. With regards pregnancy type, there was a 
significant difference in c-peptide between the non-pregnant versus normotensive pregnant 
(p<0.01) and the normotensive versus LOPE groups (p<0.01) being elevated both the pre-
eclamptic groups (EOPE +LOPE). Ghrelin did not differ across study groups (p>0.05), by HIV 
status (p>0.05). When considering HIV status, GIP varied between positive and negative groups 
(p<0.001). Additionally, there was a significant difference in GIP between the non-pregnant versus 
normotensive pregnant (p<0.01); normotensive pregnant versus EOPE (p<0.05) and the 
normotensive pregnant versus the LOPE group (p<0.01). GIP was elevated in the HIV positive 
EOPE group. Moreover, a significant difference in GLP-1 was noted across the study groups 
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(p<0.05) and between non-pregnant versus normotensive groups (p<0.01). When considering HIV 
status, HIV positive groups differed from negative study groups (p<0.05). Additionally, the Mann 
Whitney U test showed a significant difference between the non-pregnant and the normotensive 
group (p<0.01).  
 
Glucagon-like peptide-1 was significant different across the study groups, with its levels elevated 
in the pre-eclamptic groups compared to the normotensive pregnant group (p<0.05), additionally, 
there was a difference between non-pregnant versus normotensive pregnant groups (p<0.01). 
Glucagon did not differ across the study groups (p>0.05), however, was significantly different 
between the non-pregnant and normotensive group (p<0.05). HIV status did not affect glucagon 
levels (p>0.05). A significant difference between HIV positive non-pregnant and HIV negative 
non-pregnant was noted (p<0.05). 
 
Insulin was not significantly different across the study groups (p>0.05) and by HIV status 
(p>0.05). However, a significant difference between the non-pregnant versus normotensive group 
(p<0.05) was noted.  PAI-1 did not differ across the study groups (p>0.05) and between the groups 
(p>0.05). PAI-1 did not differ according to HIV status (p>0.05). A significant difference in visfatin 
across the study groups (p<0.05) and between the non-pregnant versus normotensive pregnant 
group (p<0.05) and the late onset pre-eclamptic versus the non-pregnant group (p<0.01) was 
observed. There was no effect of HIV status on the level of visfatin across the study groups 
(p<0.05). There was a significant difference between the HIV positive versus negative non-
pregnant groups (p<0.05), furthermore, we have observed low levels of visfatin in the HIV 
positive pre-eclamptic groups. 
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Discussion and conclusion: This study demonstrates elevated c-peptide, GIP, GLP-1, Insulin, PAI-1 and 
Visfatin in the pre-eclamptic groups compared to normotensive pregnant groups. These adipokines play a role 
in glucose homeostasis and have been reported to play a role in development of insulin resistance which is a 
high risk factor for developing pre-eclampsia. Several studies have reported that adipose tissue derived 
hormones, play a crucial role in the pathogenesis or as risk factors of pre-eclampsia development. Additionally, 
it is reported that adipokines are elevated in people with higher BMI (obese and overweight) which in turn 
predisposes one for developing pre-eclampsia. In terms of HIV status, we have observed that many of the 
adipokines were elevated in the HIV positive compared to the HIV negative group. This correlates with studies 
which reported that HIV plays a role in dysregulation of adipokines. In conclusion, our study is the first to 
examine adipokine dysregulation in the triad of HIV infection, pre-eclampsia and obesity. Furthermore, we 
have established that adipokines: C-peptide, GIP, GLP-1, PAI-1 and visfatin were significantly dysregulated 





































1.1 Maternal Deaths 
 
Maternal deaths is defined as the death of a woman during pregnancy or 72 days after delivery due 
to causes related to or aggravated by the pregnancy. The World Health Organisation (WHO) 
reports that every day, approximately 800 women die worldwide during, or after child delivery. 
Additionally, it is reported that women in sub-Saharan Africa are more likely to die from maternal 
deaths compared to other population areas in the world. In 2013, more than half of all maternal 
deaths occurred in Sub-Saharan Africa, and about a quarter occurred in South Asia. In 2013, 99% 
of 289,000 global maternal deaths occurred in developing countries with more than half occurring 
in sub-Saharan Africa and about a quarter in South Asia (WHO. 2014 “Maternal Mortality” Fact 
sheet 348). Additionally, it is also reported that women aged between 15–49 years in Sub-Saharan 
Africa are faced with a 2.6% chance of dying in childbirth. In Chad and Somalia, lifetime risk is 
still more than 5%, meaning that more than one woman in twenty will on average die in childbirth.    
 
The Millennium Development Goals (MDGs) set a target for the global reduction of maternal 
mortality ratio by three quarters, by the year 2015 (Post-2015 Development Agenda: Goals, 
Targets and Indicators, 2015). Despite immense progress being achieved improving maternal 
health in low and medium income countries still remains a major health challenge. Maternal deaths 
in South Africa has decreased by 50% since 2000, however this is still lower than expected target 
of 35:100 000 maternal deaths (Saving Mothers report of 2011-2013: Sixth report on confidential 
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1.1.1 Causes of maternal deaths  
 
In South Africa, the top 5 causes of maternal deaths are non-pregnant related, obstetrics 
haemorrhage, medical disorders, hypertension in pregnancy and sepsis. The latest report indicates 
that in the period of 2011-2013, the top 5 causes of maternal deaths were non-pregnancy related 
infections (NPRI) which attributed 34.7% of maternal deaths mainly due to HIV infection 
complicated by Tuberculosis (TB) and pneumonia. Secondly was obstetric haemorrhage which 
causes 15.8% of maternal deaths. This is followed by complications of hypertension in pregnancy, 
medical and surgical disorders  and sepsis causing 14.8%, 11.4% and 9.5% maternal deaths 
respectively (Saving mothers report of 2011-2013: Sixth report on confidential enquiries into 
maternal deaths in South Africa, 2015). The thesis focuses on is the conditions of pre-eclampsia, 
HIV and obesity and their impact on adipokines. 
 









1.2.1 Definition and clinical characteristics 
 
Pre-eclampsia is a hypertensive disorder exclusive to pregnancy, occurring after the 20th week of 
gestation and is one of the top 5 causes of maternal and fetal morbidity and mortality (Walsh, 
2007).  It is known as a multisystem disorder characterized by an increase in blood pressure and 
protein in the  urine (>300mg/dl) (Sibai et al., 2005).  
 
Pre-eclampsia is the most common medical condition related to pregnancy, reportedly increasing 
the risk of a mother to develop convulsions, liver and kidney failure all of which may lead to 
maternal deaths (Walsh, 2007; Williams and Pipkin, 2011). The pathogenesis of pre-eclampsia is a 
multi-factorial process that includes the interaction of genetic and environmental factors. The high 
blood pressure is a result of peripheral vasoconstriction and decreased arterial compliance (Powe et 
al., 2011). According to Moodley  (2010) both systolic and diastolic blood pressure are important 
in pregnancy induced hypertension. The proteinuria is caused by glomerular endotheliosis, due to 
the swelling of the endothelial cells of the glomerulus and the loss of endothelial fenestrations that 
contributes to a decreased glomerular filtration rate (Powe et al., 2011). 
 
Some researchers believe that immunological factors play a role in the development of pre-
eclampsia by initiating an imbalanced cascade of events between angiogenic and anti-angiogenic 
factors (Kalumba et al., 2013). Pre-eclampsia is a primigravid condition, ie., affecting women who 
are pregnant for the first time, ie., young women who are between the ages of 18-24 years.  
 
The impact of the disease is felt more severely in developing countries (Hall et al., 2014) where 
unlike other more prevalent causes of maternal mortality (such as haemorrhage and sepsis), access 
to professional medical care is difficult and medical interventions may be ineffective due to late 
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presentation. The problem is confounded by the continued mystery of the aetiology and the 
unpredictable nature of the disease. 
 
In South Africa and other developing countries, pre-eclampsia is associated with high maternal and 
neonatal mortality and morbidity (Hall et al., 2014; Kalumba et al., 2013; Young et al., 2010). 
There is no cure for pre-eclampsia, the current resolution is delivery of the placenta.  Early delivery 
of the fetus is usually recommended for women who have severe pre-eclampsia. Both mother and 
child have a risk of developing serious cardiovascular and metabolic complications (Sibai et al., 
2005). Other complications associated with pre-eclampsia include eclampsia, hemolysis, elevated 
liver enzymes, and low platelets (HELLP) syndrome, acute renal failure, hepatic enzymes de-
rangement, abruptio placenta, disseminated intravascular coagulation (DIC) and maternal death. 
Perinatal complications include preterm delivery, low birth weight, intrauterine fetal death (IUFD) 
and neonatal deaths.  
 
1.2.2 Signs & Symptoms 
The fact that pre-eclampsia has a variety of aetiologies and its presentation may vary, makes 
diagnosis difficult (Young et al., 2010). Pre-eclampsia may present itself as a mild to severe 
disease, whilst in some women it may lack the cardinal signs and symptoms (Trogstad et al., 2011; 
Young et al., 2010). Pre-eclampsia has no resilient diagnostic test, and the key features that have 
been used to diagnose this condition are the inception of hypertension and proteinuria in pregnancy 
(Moodley, 2010; Young et al., 2010) Previously, oedema used  to be used as a diagnostic triad for 
pre-eclampsia, but was found to be problematic due to the fact that oedema is not only specific to 
pre-eclamptic patients, as normotensive women also present with oedema during pregnancy 
(Young et al., 2010). Currently the clinical signs used for the diagnosis of pre-eclampsia are 
hypertension, proteinuria, glomerular endotheliosis, HELLP (Young et al., 2010). Hypertension 
and proteinuria are at a diagnostic level in pregnancy when they both present as new onset systolic 
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blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg and ≥300 mg/24hours of protein 
in a 24 hour urine specimen (Moodley, 2010; Young et al., 2010) 
Pre-eclampsia has a wide clinical spectrum and in most circumstances presents as a mild disease 
with few clinical signs (Trogstad et al., 2011; Young et al., 2010). In severe cases of pre-eclampsia 
women may develop headaches or visual changes, pain in the upper abdomen arising from acute 
liver injury, pulmonary oedema, acute renal failure, haemolysis and/or thrombocytopenia (Young 
et al., 2010). In severe pre-eclampsia, convulsions may occur, the condition is then referred to as 
eclampsia with resultant severe complications even postpartum.  
 
1.2.3 Risk Factors 
Despite years of intensive research on pre-eclampsia, its risk factors and aetiology are still not yet 
fully understood (Powe et al., 2011; Trogstad et al., 2011). Several medical conditions and 
preferences of certain lifestyles are associated with increased risk of pre-eclampsia development. 
August and Sibai (2013) state that the magnitude of each risk factor depends upon genetic factors, 
disease recurrence, multiple gestation etc. (Trogstad et al., 2011). The age at which a female 
conceives is a major factor that determines manifestation of the disease, most studies have shown 
that pre-eclampsia predominates in young women, first pregnancies and advanced maternal age 
(Young et al., 2010). 
 
Pre-existing hypertension disorders, metabolic disorders, diabetes mellitus, obesity and renal 
diseases are medical conditions associated with an increased risk of pre-eclampsia development 
(Trogstad et al., 2011; Young et al., 2010).  
 
Obstetric conditions such as increased placental mass, mole development within the uterus and a 
multi-fetal pregnancy increases ones risk  (Trogstad et al., 2011; Young et al., 2010).  England and 
associates demonstrated that smoking is a protective mechanism against pre-eclampsia 
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development (England et al., 2002). Yet this fact can be intensively debated as smoking may 
indirectly increase the risk of the woman acquiring predisposing disorders of pre-eclampsia like 
cardiovascular diseases later in life. Studies have shown that neonatal mortality rate of babies born 







Globally, pre-eclampsia affects 7-10% of pregnant women and is a leading cause of maternal and 
perinatal mortality and morbidity (Kalumba et al., 2013). Although a reduction in maternal death 
has been reported since the Millenium Development Goals (MDGs) in high income countries, there 
is still a high rate of maternal deaths in low to middle income countries. Pre-eclampsia is more 
prevalent in developing countries due to limitations of access to health care, which results in an 
estimated >60 000 maternal deaths per annum (Young et al., 2010). In developed countries, access 
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Figure 1.2: Graphic illustration of the global and regional statistics of maternal deaths due to pre-
eclampsia (Source: The Lancet Global health, June 2014). 
 
1.2.3.2 Pre-eclampsia in sub-Saharan Africa 
In developing countries, the incidence of pre-eclampsia is high posing as a serious threat to the 
health of pregnant women. According to the World Health Organization (WHO), in 2010, 
approximately 287,000 women died in pregnancy and childbirth (http:// 
lifeofafricamothers.org/maternal health). It is reported that more than half of women affected by 
pre-eclampsia have poor access to health care, hence they are not diagnosed early enough to 
receive good management of the condition (Moodley, 2010). In general, sub-Saharan African 
countries are under-resourced and provision of health care facilities is poor. Moreover, 
unavailability of some medication and a lack of standard protocol of management of pre-eclampsia 
contribute to the high maternal deaths (Moodley, 2010) .   
 
In South Africa, hypertension is the second direct cause of maternal death (14%), among pregnant 
women with eighty three percent been attributed to pre-eclampsia (Govender et al., 2013). 
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Moreover, in South Africa, maternal deaths due to pre-eclampsia are more common among 
younger than older women (Saving Mother’s Report; 2012). Teenage pregnancy is a major 
problem in African countries providing a plausible reason why pre-eclampsia is common among 
younger women.  
 
In KwaZulu-Natal, pre-eclampsia is a common condition in the obstetric care unit.  Sixteen percent 
of all hypertensive patients at the maternity unit of King Edward VIII and 12% Prince Mshiyeni 
Memorial Hospital (PMMH) suffer from hypertension in pregnancy. 
 
1.2.4 Pathogenesis 
In recent years the pathogenesis of this condition has been better explored (Athukorala et al., 
2010). The disease originates in the placenta (Powe et al., 2011; Trogstad et al., 2011; Young et al., 
2010). 
 
Pre-eclampsia pathogenesis includes abnormal placentation, cardiovascular problems, 
maladaptation to pregnancy, genetic and immune mechanisms, an enhanced systemic inflammatory 
response, and nutritional, hormonal and angiogenic factors (Appay and Sauce, 2008). The maternal 
systemic inflammatory response, endothelial cell dysfunction and increased coagulation is 
secondary to abnormal placental function (Moodley, 2010).  Extravillous cyotrophoblast migration 
and invasion of the decidual myometrial junction is limited in pre-eclampsia (Naicker et al., 2003). 
Moodley (2013), proposed that pre-eclampsia is a two stage disorder; viz., inadequate vascular 
remodelling of the spiral arterioles in the placental bed, hence reduction of blood flow to the 
placenta with resultant hypoxic environment and inadequate oxygen and nutrient supply to the 
fetus. This is followed by a cascade of events with resultant oxidative stress, widespread damage to 
the endothelium and consequential maternal signs and symptoms of pre-eclampsia. 
 
The key purpose of the placenta is the transfer of nutrients and vital gases to the developing fetus, 
and also the elimination of waste through the mother’s blood supply. The placenta of women with 
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severe pre-eclampsia are associated with infarcts, inflammation, and haemorrhage/blood clot 
(Powe et al., 2011). 
 
In normal pregnancy cytrophoblasts arising from the tips of the anchoring villi throught the 
decidua into the myometrium and invade the maternal spiral arterioles. This invasion results in the 
cytotrophoblast adopting a vascular phenotype and the muscular tunica media is replaced by a 
fibrinoid type material (Lam et al., 2005). The spiral arteries are remodelled into large-capacitance, 
low-resistance vessels, a feature referred to as a physiological conversion. The placenta releases 
high levels of anti-angiogenic factors and low levels of pro-angiogenic factors, thus contradicting 
the process of angiogenesis and disrupting the maternal endothelium (Young et al., 2010). The 
reason for the modification from the usual angiogenic stability into an anti-angiogenic state is not 
known (Young et al., 2010). This shift however, is said to be the main cause of the maternal 
hypertensive syndrome, proteinuria as well as other clinical signs of pre-eclampsia and eclampsia 
(Young et al., 2010). 
 
In pre-eclampsia however, there is an abnormal trophoblast cell migration due to the fact that 
cytotrophoblasts fail to adopt an invasive phenotype. This results in shallow invasion of the spiral 
arteries and the myometrial arteries remain as small-caliber, resistance vessels, which then leads to 
poor blood flow to meet the growing demands of the fetus.  
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Figure 1.3: Trophoblast invasion/migration in normal pregnancy versus abnormal pregnancy in the 
case of pre-eclampsia, image adapted from (www.sciencemag.org/latest advances in understanding 
pre-eclampsia). 
 
 1.2.4 Management 
Currently, the management of  pre-eclampsia is timely diagnosis, proper management and early 
delivery,  to prevent complications (Sibai et al., 2005; Trogstad et al., 2011; Young et al., 2010). A 
decision of induced premature delivery is mostly used in developed countries to protect the health 
of the mother, this method has shown to have adverse results in the survival of the neonate and 
may result in low birth weight, morbidity and/or mortality (Powe et al., 2011; Young et al., 2010). 
Close monitoring of the fetus using ultrasound examination and fetal heart rate testing is crucial 
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1.3 Human Immunodeficiency Virus 
 
 
1.3.1 Definition and clinical characteristics 
Human immunodeficiency virus (HIV) infection is an immune-dysfunction pandemic that has 
affected and infected millions of people worldwide. It was discovered in 1981 and has since been a 
major threat to human health globally but it more common in African countries. HIV-1 accounts 
for 95% of infections worldwide and characterized by a depletion of CD4+ T cells (Appay and 
Sauce, 2008). Cells that express CD4+ include T helper cells, macrophages and dendritic cells, and 
are important in the effective functioning of the immune system. T helper cells are especially 
essential for activating B cells to produce antibodies.  The production of antibodies is the hallmark 
for the execution of the whole immune system, failure of the T helper cells to activate B cells 




Figure 1.4: Figure demonstrating the mechanism of HIV-1 and host cell interaction (Source: 
Sheehy et al., 2002). 
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Figure 1.5: Graph showing the burden of HIV prevalence and incidences globally and regionally 
(Source: http://www.who.int/gho/hiv/en/). 
 
1.4 HIV and Pregnancy 
 
According to the South African Saving Mother’s report (2012), HIV is the most common 
underlying condition associated with maternal deaths (39%). HIV/AIDS may influence maternal 
mortality in several ways. HIV can influence maternal death in HIV positive women by making 
them more susceptible to direct or obstetric causes of maternal mortality, such as post-partum 
haemorrhage, puerperal sepsis and complications of caesarean section. It is plausible to suggest 
that the hyperimmune reactivity in pre-eclampsia may be neutralised by the immunocompromised 
state of HIV infection. Kalumba and associates suggests that HIV provides some sort of immunity 
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against pre-eclampsia, thus HIV positive women are at a lower risk of developing pre-eclampsia 
than the general population (Kalumba et al., 2013) .  
 
HIV and pre-eclampsia, are common conditions in developing countries especially Sub-Saharan 
African countries. Pre-eclampsia was more common in HIV negative pregnant women (Hall et al., 
2014; Kalumba et al., 2013). These findings support the idea that pre-eclampsia which has a major 
proliferative aseptic inflammation cannot progress enough on immunocompromised ground. 
Nevertheless, recent studies have shown no difference on the prevalence of pre-eclampsia in HIV 
negative and HIV positive women. A study by Hall and associates (Hall et al., 2014) show that 
women on anti-retroviral therapy were at lower risk of developing pre-eclampsia. In contrast, a 
study by Boyajian and associates indicated that HIV positive woman developed a more severe 
form of pre-eclampsia (Boyajian et al., 2012). To date, there has been no agreement on the link of 
HIV infection regarding pre-eclampsia progression. Although the aetiology of pre-eclampsia is not 
fully understood, hyper-reactivity of the immune system is presumed to be involved in the 
progression of pre-eclampsia (Appay and Sauce, 2008). Therefore, in the case of HIV infection the 
associated immune deficiency may neutralize the immune hyper reactivity of pre-eclampsia (Hall 
et al., 2014). 
 
Based on a retrospective study done by Kalumba et al., (2013), in South Africa, approximately 
30% of antenatal patients are infected with HIV. This study is relevant in South Africa, because 
both HIV and pre-eclampsia are the most common indirect and direct causes of maternal deaths 
respectively (Govender et al., 2013; Kalumba et al., 2013) hence South Africa represents an ideal 
site for a study involving HIV and pre-eclampsia. Moreover, the province of KwaZulu-Natal 
represents the epicentre of the global HIV pandemic and our province has a 12% incidence of pre-
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1.5 Adipokines 
Adipokines are cytokines or secretory protein hormones that are produced by adipose tissue.  It 
may also be referred to as adipocytokines (Haugen, 2005). They include c-peptide, ghrelin, gastric 
inhibitory polypeptide (GIP), glucagon like peptide (GLP)-1, glucagon, insulin, plasminogen 
activator inhibitor (PAI)-1, resistin, adipsin, leptin and visfatin.  Adipokines are involved in lipid 
metabolism, insulin sensitivity, the alternative complement system, vascular haemostasis, blood 
pressure regulation and angiogenesis, as well as the regulation of energy balance (Haugen, 2005). 
They implicated in the regulation of satiety, appetite, physical activity and energy expenditure. 
Adipokines also influence metabolic disease, cardiovascular disease and insulin resistance (EI-
Shafe et al., 2014). Adipokines are also produced by other organs, for example, during pregnancy 
adipokines are produced by the placenta, because the body has to adjust in order to meet the 
demands of the both mother and child. 
 
Figure 1.6: The adipose tissue and the cytokines/protein hormones that are produced by it. These 
cytokines play various roles in the body, some like TNFα plays an essential in the activation of the 
immune system which contributes to antigen/pathogen clearance. Some, like glucagon-like 
peptide-1, visfatin play a crucial role in the homeostasis of glucose metabolism. Image adapted 
from (www.medscape.org) 
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1.5.1 Adipokines & Pregnancy 
During pregnancy, the placenta produces these adipokines. Adipocyte-secreted factors play a key 
role in the development of pathogenesis of pre-eclampsia (Fasshauer et al., 2008). During 
pregnancy, women experience an increase in weight, body fat mass, and insulin resistance. Leptin 
is responsible for regulating food intake and body weight and is elevated in pre-eclamptic women. 
Moreover  women who are overweight/obese have an increased risk of difficult pregnancy 
outcomes (Athukorala et al., 2010) 
 
 
1.5.2 Adipokines, HIV and pre-eclampsia 
In HIV infection, adipose tissue and the resultant adipokines are dysregulated due to lipoatropy. 
Exacerbating this condition is the fact that patients on long term anti-HIV therapy experience 
lipoatrophy (Lake and Currier, 2013). Lipohypertrophy is a result of adipose tissue perturbations, 
including increased fibrosis without inflammation, increased small adipocyte numbers, and 
decreased vascularity. The increase in lipid production increases the risk of cardiovascular disease 
development among HIV positive patients on ART treatment with resultant death.  
 
The mechanism by which metabolic perturbations of adipose occur is not yet understood. This 
study compares C-peptide, Ghrelin, gastric inhibitory polypeptide (GIP), glucagon like peptide-1 
(GLP-1), Glucagon, Insulin, plasminogen activator inhibitor-1 (Pal-1) and Visfatin levels in non-




C-peptide is a short protein that is reportedly formed during the biosynthesis of insulin. C-peptide 
is a 30-35 amino acid sequence molecule. The signal sequence of C-peptide is cleaved from the N-
terminus by a signal peptidase, following cleavage it leaves pro-insulin, the A-chain and B-chain 
are left bound together by disulphide bonds that constitute the insulin molecule (Kunt et al., 1999). 
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The main function of c-peptide is to connect insulin's A-chain to its B-chain in the pro-insulin 
molecule (Kunt et al., 1999).  C-peptide has a half-life of 30 minutes which is really high 
compared nsto iulin which has a half-life of 5 minutes (Valensise et al., 2002). Together with 
insulin, C-peptide is stored in secretory granules of the pancreatic beta cells and are released into 
the portal circulation.  
 
Since c-peptide is responsible for activating insulin, it is plausible to suggest that it may be used as 
a marker to measure insulin activity (Valensise et al., 2002). Moreover, c-peptide together with 




Figure 1.7: Mechanism mechanism of action of c-peptide. C-peptide binds to a cell membrane 
receptor which is coupled to a G-protein. This leads to the activation of calcium channels or cause 
the release of calcium from intracellular stores resulting in increased intracellular calcium and 
activation of calcium dependent protein phosphate IIB which turn, converts inactive 








Ghrelin is a hunger-stimulating peptide (also known as appetite-regulating hormone) made up of 
28-amino acids, in which Ser 3 is modified by a fatty acid n-octanoic acid (Kojima and Kangawa, 
2005). It consists of a bulky hydrophilic side-chain group which plays an essential role in its 
activity. Ghrelin is produced mainly by the cells lining the fundus of the human stomach and 
epsilon cells of the pancreas. Its receptors are expressed in a wide variety of tissues, including the 
pancreas, thyroid, pituitary, stomach, heart, thymus, intestine, hypothalamus, hippocampus and 
gonads.  
 
Ghrelin is well-known for its role in stimulating the release of growth hormone hence also known 
as growth hormone secretagogues (GHSs) (Kojima and Kangawa, 2005). This occurs via an 
alternative pathway from that of growth hormone releasing hormone (GHRH), suggesting that it 
can be used in treatment of growth hormone deficiency. Ghrelin acts through the growth hormone 
secretagogues receptor (GHS-R) via G protein coupled receptors located in diverse areas of the 
body, hence have diverse biological functions (Kojima and Kangawa, 2005). Falasca et al., (2006) 
found that ghrelin initiates the pathogenesis of metabolic disorders in HIV-infected patients by 
inducing metabolic abnormalities. Furthermore, studies have shown that the levels of ghrelin are 
reduced in lipodystrophy among HIV positive patients, resulting in fat redistribution (Koutkia, 
2004).  
 
 Antiretroviral therapy (ARV) treatment contributes to low ghrelin levels among HIV positive 
participants. Ghrelin is considered to be the counterpart of the hormone leptin because its levels are 
high before meals and decreases right after a meal, indicating that it transmits a hunger signal from 
the periphery to the central nervous system, hence is sometimes referred to as orexigenic hormone. 
Based on Wang et al., (2013), this elevation regulates various physiological processes such as 
increasing sympathetic activity and mitochondrial superoxide synthesis, inducing expansion of Th1 
cells secreting pro-inflammatory cytokines and activating expression of matrix metalloproteases 
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(MMPs) and tissue MMP inhibitors, thus modulating vascular structure. These alterations 





Figure 1.8: The mechanism of action of ghrelin. Adapted from (St-Pierre et al., 2003) 
 
1.5.5 Gastric inhibitory polypeptide (GIP) 
GIP is an incretin hormone that is also known as the glucose-dependent insulinotropic peptide. It is 
produced by cells which are found in the mucosa of the duodenum and the jejunum of the 
gastrointestinal tract and its receptors are found in the beta cells of the pancreas (Kieffer, 2004). 
Receptors for GIP are expressed on pancreatic beta cells, where binding of GIP results in the 
activation of adenyl cycles leading to increase in cyclic AMP levels and resultant stimulation of 
insulin release, which increases the uptake of glucose by the liver, brain and kidney cells, 
eventuating in the production of glycogen and fat production 
 
In cases where the receptors of GIP are disrupted, glucose intolerance occurs (Kieffer, 2004), 
probably because when GIP is not evoking increased in cAMP, the production of insulin is low due 
to reduced incretin effect. Furthermore, low insulin production is associated with high blood sugar 
levels. Several studies have implicated GIP or GIP receptor disruption in the pathogenesis of type 2 
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diabetes (Kieffer, 2004). Notably, some studies have reported that GIP alone does not account for 




Figure 1.9: Mechanism of action of GIP in normal and abnormal conditions (www.pnas.org) 
 
1.5.6 Glucagon-like peptide 1(GLP-1) 
In the early 1980’s, during the cloning of anglerfish pre-proglucagons, the scientist observed that 
the molecule being cloned, in addition to glucagon, contained a glucagon-related peptide which 
appeared to have strong homology to the sequence of GIP (Kieffer, 2004). Additionally, the similar 
resemblance to GIP homology sequence suggested that the molecule might be an intestinal incretin 
hormone. According to Kieffer (2004), the notion that the molecule is an incretin hormone was 
highly welcomed by the scientific community since other investigators have observed similar pre-
proglucagons mRNAs were expressed in the anglerfish pancrease and intestine. Furthermore, 
mammalian pre-proglucagons were subsequently cloned and were termed glucagon-like peptides. 
In 1987, it was demonstrated that that GLP-1, just like GIP, is a potent insulinotropic hormone 
(Marathe et al., 2013). According to Kieffer (2004), GLP-1 is produced by intestinal L cells during 
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post translational processing of pro-glucagon. Following that, the molecule was name glucagon-
like peptide (GLP)-1 (Kieffer, 2004).  
 
Its release is stimulated in response to feeding, suggesting that it plays a role in the control of blood 
glucose level. Receptors of GLP-1 are also found in the hypothalamus, brain and in areas without a 
blood-brain barrier. GIP-1 has several physiological functions which include; increasing insulin 
secretion from the pancreas in a glucose-dependent manner, decreasing glucagon secretion from 
the pancreas by engaging specific G protein-coupled receptor and increasing insulin-sensitivity in 
both alpha cells, and beta cells and decreasing food intake by increasing satiety in brain 
(MacDonald et al., 2002). GLP-1 is found in milk and according to Schueler et al., (2013). 
Additionally, breast milk fed babies regulate their weight better than formula fed babies, hence less 




Figure 1.10: An illustration of the mechanism of action of GLP-1. GLP-1 increase the secretion of 
insulin secretion in pancreatic beta cells (Drucker & Nauck, 2006). 
 





Insulin is a peptide hormone that was named by Sir Edward Schafer, additionally, he described the 
actions of insulin. In 1921, it was discovered by Banting and Best, the details of insulin discovery 
are highlighted/outlined in further by Karamitsos (2011). It plays a crucial role in the regulation of 
metabolism of carbohydrates and fats by increase the uptake of glucose by the cells, glycogenesis, 
lipogenesis and inhibition of production of glucose by the liver (Sonksen and Sonksen, 2000). The 
human insulin protein is composed of 51 amino acids, and has a molecular mass of 5808 Da. It is a 
dimer of an A-chain and a B-chain, which are linked together by disulfide bonds (Kunt et al., 
1999). Insulin's structure varies slightly between species of animals. Insulin from animal sources 
differs somewhat in "strength" (in carbohydrate metabolism control effects) from that in humans 
because of those variations. Porcine insulin is especially close to the human version. 
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1.5.7.1 Insulin secretion and receptors 
Insulin is secreted by the Islets of Langerhans of pancreas beta cells, it is normally released during 
food ingestion and when blood glucose levels are rising, except in the case of diabetes mellitus and 
metabolic syndrome. It comprises of two polypeptide chains namely; A- and B- chains, which are 
linked together by disulfide bonds. According to Kunt et al., (1999), insulin is first produced as a 
single polypeptide called pre-proinsulin which contains a 24-residue signal peptide which is 
responsible for directing the nascent polypeptide chain to the rough endoplasmic reticulum (RER).  
The pro-insulin molecule is cleaved in the secretory granules into equimolar amounts of insulin 
and c-peptide (Kunt et al., 1999). 
 
When control of insulin levels fails, diabetes mellitus can result. As a consequence, insulin is used 
medically to treat some forms of diabetes mellitus. Patients with type 1 diabetes depend on external 
insulin (most commonly injected subcutaneously) for their survival because the hormone is no 
longer produced internally. Patients with type 2 diabetes are often insulin resistant and, because of 
such resistance, may suffer from a "relative" insulin deficiency. Some patients with type 2 diabetes 
may eventually require insulin if dietary modifications or other medications fail to control blood 
glucose levels adequately. Over 40% of those with Type 2 diabetes require insulin as part of their 
diabetes management plan. 
 
Previous studies have shown a connection between the increased frequency of type 2 diabetes in 
women with a history of pre-eclampsia. Carr  and associates reports that the degree of insulin 
sensitivity determines glucose metabolism (Carr et al., 2011). A decrease in insulin sensitivity is 
associated with high levels of blood glucose and this subjects pregnant women to a greater risk of 
developing pre-eclampsia. Long exposure to antiretroviral therapy (ART) specifically protease 
inhibitors is associated with insulin resistance among HIV infected patients (Schueler et al., 2013); 
(van Zoelen et al., 2013). Factors such as obesity and physical inactivity, immune dysregulation 
and inflammation contribute to the increased prevalence of insulin resistance and diabetes in HIV 
infected patients (Hall et al., 2014; Young et al., 2010).  
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 1.5.8 Glucagon 
Glucagon is a 29-amino acid polypeptide produced by the alpha cells of the pancreas. Its primary 
structure in humans is: NH2-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-
Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-COOH. It is an insulin antagonist, 
increasing blood glucose unlike insulin which decreases blood glucose levels (Reece and 
Campbelle, 2002). Glucagon was initially discovered by Kimball and Murlin in 1920 but was only 
officially documented in 1923. In tandem with insulin it regulates blood glucose level, ie., insulin 
release is stimulated by high glucose levels (e.g. after eating) whilst glucagon release is stimulated 
by low blood glucose levels (e.g. during starvation). Glucagon causes the liver to convert stored 
glycogen into glucose, which is released into the bloodstream. High blood glucose levels stimulate 
the release of insulin. Insulin allows glucose to be taken up and used by insulin-dependent tissues. 
Thus, glucagon and insulin are part of a feedback system that keeps blood glucose levels at a stable 
level. 
 
Glucagon elevates the concentration of glucose in the blood by promoting gluconeogenesis and 
glycogenolysis.  It accomplishes this by binding to glucagon receptors and stimulating liver cells to 
convert glycogen into glucose with subsequent release into the bloodstream, in a process known as 
glycogenolysis. When glucose stores in the liver run out, glucagon levels turn-off glycolysis in the 
liver and then encourages the liver and kidney to produce additional glucose through a process 
known as gluconeogenesis. Additionally, glucagon is also responsible for regulating the rate of 
glucose production through the breakdown of fats (Liljenquist et al., 1974). Elevated levels of 
glucagon are associated with conditions such as pancreatic tumours and glucagonoma. 
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Figure 1.12: Amino acid sequence of glucagon (www.diapedia.org). Glucagon is a 29-amino acid 




Figure 1.13 Schematic outline of the mechanism of action of peptide hormone, glucagon. Adapted 
from (www.dipedia.org). 
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1.5.9 Plasminogen activator inhibitor (PAI)-1 
 
1.5.9.1 Background information 
PAI-1 is a serine protease inhibitor protein that is encoded by serine protease inhibitor protein 
SERPINE 1 gene in humans and is also known as endothelial plasminogen activator inhibitor-1 or 
SERPINE 1. The SERPINE1 gene is reportedly located on chromosome 7. Knudsen and 
colleagues reported that PAI-1 is the main inhibitor of the tissue plasminogen activator, which 
prevents the natural degradation of thrombin (Knudsen et al., 2014). Receptors of PAI-1 are 
expressed in several tissues such as the liver, lung, heart, kidney, platelets and adipose tissue 
(Samad & Loskutoff, 1996). Its regulators include cytokines, growth factors, hormones, 
endotoxins, glucocorticoids, angiotensin, p53 and fatty acids (Sandberg et al., 1997; Loskutoff & 
Samad, 1998). 
 
PAI-1 is also a principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), 
which are the activators of plasminogen and hence fibrolysis. Fibrolysis is known as the 
physiological breakdown of blood clots. It also plays a crucial role in the extracellular matrix 
remodelling. It is synthesized by the endothelial cells and is present in plasma and in blood 
platelets. It is also known as endothelial plasminogen activator inhibitor and is said to be associated 
with decrease fibrinolytic activity of euglobulins. 
 
1.5.9.2 Synthesis and secretion 
PAI-1 is one of the earliest inflammation response genes, stimulated by cytokines, growth factors 
and endotoxins. It is mainly produced by the endothelium, but it is also secreted by other tissue 
types such as adipose tissue.  PAI-1 can convert to a stable latent form automatically. Its deficiency 
is associated with abnormal bleeding, which has been observed in patients that are homozygous for 
the PAI-1 gene (Fay et al., 1997). Another function of PAI-1 is that it inhibits the activity of the 
 
27 | P a g e  
 
matrix metalloproteinases, which reportedly play a crucial role in the invasion of malignant cells 
across the basal lamina.  
 
In obesity, PAI-1 levels are reportedly elevated which leads to metabolic syndrome. Risk of 
thrombosis is high in obesity and in metabolic syndromes. Additionally, angiotensin 2 increases 
the synthesis of PAI-1, resulting in accelerated risk of atherosclerosis development. Furthermore, 
studies have shown/ reported that increased levels of PAI-1 are associated with arterial 
hypertension. 
 
1.5.9..3 Over-expression of PAI-1 
The expression of PAI-1 is regulated by EGF and TGF-beta, it is reported that alteration in the 
gene expression of PAI-1 and its elevation, are associated with fibrosis and metabolic syndromes. 
Thus elevated levels of PAI-1 are associated with increased risk of developing conditions such as 
thrombosis and atherosclerosis. Additionally, previous studies have demonstrated PAI-1 as a 
potential biomarker of endothelial dysfunction, inflammation and coagulation which are associated 
with atherosclerosis, pre-eclampsia and cardiovascular diseases.   
 
According to Knudsen and associates (2014), elevated levels of PAI-1 are associated with high 
levels of first time myocardial infarction in HIV-1 infected individuals. They report that HIV is 
associated with high chronic state of inflammation, immune activation via TNF-alpha. Individuals 
who are HIV positive and or on ART have even higher markers of endothelial dsyfunction, 
however the mechanistic effect of ART on endothelial dysfunction markers still requires clarity. 
Some suggest that, regardless of whether a person receives anti-HIV treatment or not, the mere fact 
that HIV is associated with inflammation and activation of immune cells will lead to increase in 
markers of endothelial dysfuntion elucidating to the fact that infection alone can increase the levels 
of PAI-1. Nonetheless, there seem to be an association between HIV positive individuals on ART 
and the development of first time myocardial infarction (Herrari et al.., 2003). Another plausible 
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suggestion is that HIV infected individuals only have elevated PAI-1 levels after years of chronic 
inflammation state in HIV-1 infected individuals. Furthermore, Gudinchet et al., (1988), reported 
that PAI-1 is associated with multiple sclerosis in the nervous system. During pregnancy profound 
alterations of the coagulation and the fibrinolytic system occur and elevated levels of PAI-1 during 
pregnancy are associated with miscarriage. 
 
1.5.9.4 PAI-1 gene polymorphism and adverse pregnancy outcomes 
There is reportedly a common deletion polymorphism that results in a sequence of 4G instead of 
5G in the promoter region of the gene associated with small increase in the risk of venous 
thromboembolism (Said et al., 2012). Some studies have reported that this polymorphism is 
associated with adverse pregnancy outcomes, however, the topic remains controversial. In the 
study by Said and colleages, women were genotyped for the 4G/5G polymorphism and no 
association was found (Said et al., 2012).  
 
Notably, it is reported that the polymorphism does not alter the gene expression of PAI-1, however, 
it alters the expression which is reportedly a high risk for thrombosis which is associated with high 
risk of venous thromboembolism and coronary artery disease which can significantly affect 
pregnancy outcome. 
 
During pregnancy, profound changes take place in the hemostatic system and the level of PAI-1 
increases (Kruithof et al., 1987). In general, normal pregnancy is said to be associated with a 
reduction in fibrinylysis, which is due to an increase in fibrinolytic inhibitors particularly PAI-1 
which is responsible for inhibiting plasminogen, this results in the reduction in the activation and 
production of plasminogen to plasmin which is associated with thromboembolism (Kruithof et al., 
1987). Fibrinolytic activity during pregnancy decreases, due to increase levels of PAI-1 derived 
from the placenta and from an increase of fibrinogen factor VII and VIII and the Von Willebrand’s 
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factor. PAI-1 is associated with the development of severe pre-eclampsia and consequentially with 




Figure 1.14: PAI-1 mechanism of action in the cell migration pathway. (Czekay et al., 2011). 
 
1.5.10 Visfatin   
 
Visfatin is an enzyme/cytokine produced by adipose tissue. It is also known as 
nicotinamidephosphor-ribosyltransferase (NAmPRTase or Nampt) or as as pre-B-cell colony-
enhancing factor 1(PBEF1), additionally, It is also implicated in nicotinate and nicotinamide 
metabolism (Zulfıkaroglu et al., 2010). NAmPRTase catalyzes the condensation of nicotinamide 
with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the 
biosynthesis of nicotinamide adenine dinucleotide. Visfatin is involved in the regulation of glucose 
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homeostasis because it has insulin-mimicking effect through the activation of an insulin receptor 
(Zulfıkaroglu et al., 2010). The protein is an adipokine that is localized to the bloodstream and has 
various functions, including the promotion of vascular smooth muscle cell maturation and 
inhibition of neutrophil apoptosis. Visfatin is expressed in the brain, lung, kidney, spleen, testes 
etc, but it reportedly expressed more in visceral adipose tissue than any other organ and elevated 
levels of this protein have been reported correlate with obesity (Fasshauer et al., 2007).  
 
It is also responsible for the promotion of B cell maturation and is linked with the pathogenesis of 
type 2 diabetes through its role in the pathophysiology of insulin resistance, especially among 
obese individuals (EI-Shafey et al., 2014). Off note, diabetes type 2 is more prevalent in obese 
individuals who are allied to high expression of adipose tissue derived cytokines/factors, it is 
therefore plausible to suggest that individuals with higher BMI will express high levels of visfatin 
hence higher have a higher risk of becoming insulin resistance and developing diabetes type 2 
(Fasshauer et al., 2007).Visfatin dysregulation in patients with insulin resistance may mediate 
predisposition to pre-eclampsia development. Visfatin levels are elevated in pregnancies especially 
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1.11 Aims, objectives and null hypothesis  
 
1.11.1 Aims  
 
To compare the level of adipokines viz., C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, Pal-1 
and Visfatin in non-pregnant, normotensive pregnant and pre-eclamptic women infected and 




 To determine the maternal serum levels of adipokines (C-peptide, Ghrelin, GIP, GLP-1, 
Glucagon, Insulin, Pal-1 and Visfatin) across all study groups. 
 To compare maternal serum levels of C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, 
Pal-1 and Visfatin in normotensive pregnant compared to the non-pregnant women. 
 To compare maternal serum levels of C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, 
Pal-1 and Visfatin in HIV positive women matched with HIV negative normotensive 
pregnant women. 
 To compare maternal serum levels of C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, 
Pal-1 and Visfatin in HIV associated pre-eclampsia compared to HIV negative pre-
eclamptic patients. 
 To compare maternal serum levels of C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, 
Pal-1 and Visfatin in patients with early onset and compare to patients with late onset pre-
eclampsia. 
 To compare maternal serum levels of C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, 
Pal-1 and Visfatin in pre-eclamptic participants versus normotensive participants 
 To compare maternal serum levels of C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, 
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1.11.3 Null Hypothesis 
 
The maternal serum levels of C-peptide, Ghrelin, GIP, GLP-1, Glucagon, Insulin, Pal-1 and 
Visfatin will remain unchanged across all groups irrespective of HIV status and type of pregnancy 
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MATERIALS AND METHODS 
 
2.1 Study design 
 
 This is a retrospective experimental study that utilises blood archived from a previous study 
(BE256/12).  The blood was obtained from pregnant Black South African women attending the RK 
Khan Hospital (KwaZulu-Natal, South Africa). Following approval by the institutional Biomedical 
Research Ethics Committee (Ethics reference no: BE256/12; appendix 1), Department of Health 
(appendix 2) and the medical superintendent (appendix 3) the study commenced. Informed patient 
consent was obtained from all women (appendix 4). 
 
 
2.1.1 Recruitment of participants 
 
Pregnant women were recruited at their first antenatal visit at the Obstetric Unit, RK Khan 
Hospital. Only primiparous women over 18 years of age were enrolled in the study, after signing 
informed written consent forms. The non-pregnant group was recruited from the family planning 
clinic, RK Khan Hospital.  
 
Women were first screened and counselled before being offered entry into the study. Patient 
demographics (ethnicity, age, blood pressure, gestational age, maternal weight, body mass index 
(BMI) at first visit, fasting glucose tolerance test, fasting insulin levels, HIV status, CD4 counts 
and ARV / PMTCT use as appropriate) was collated on a formal patient data sheet (appendix 5).  
 
2.2 Study population 
 
The study population was divided into two main study groups, the pregnant and non-pregnant 
(Figure 2.1). The pregnant group was subdivided into the pre-eclamptic and the normotensive 
groups. The pre-eclamptic group was further subdivided into early onset and late onset pre-
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eclamptic groups. These subgroups underwent stratification into HIV positive and HIV negative 
groups.  
 
Non pregnant participants were eligible for entry provided they were between 18 – 45y, did not 
have hypertension, were not being treated for a chronic illness including endocrinopathies or 
cancer and were more than six weeks post partum.  
 
Figure 2.1: Schematic outline of study population of our study. 
 
 
2.2.1 Inclusion criteria 
 
Inclusion criteria for pre-eclampsia included the new onset of hypertension (BP ≥ 140/90 mmHg) 
and proteinuria after 20 weeks of gestation (proteinuria of at least 1+ on dipstick). HIV positive 
participants were sub categorized according to their CD4 count (i.e. ≥ 200 or < 200) within each 
cohort. 
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2.2.2 Exclusion criteria 
 
Women who had chronic hypertension, were non-black African, had gestational diabetic, chronic 
diabetic, unknown HIV status, chorioamnionitis, polycystic ovarian syndrome, thyroid disorders, 
chronic renal disease, cardiac failure, connective tissue disease / antiphospholipid syndrome and 
abruptio placentae were excluded from the study. 
 
2.3 Sample collection and preparation 
 
Blood samples were collected from the women by an obstetrician and gynecologist at the Obstetric 
Unit, RK Khan Hospital and delivered to the Optics and Imaging Centre, Doris Duke Medical 
Research Centre, University of KwaZulu-Natal within 2 hours of collection.  
 
The samples were then centrifuged at 3000 revolutions per minute (rpm) for 10 min. Following 
centrifugation, plasma, serum and buffy coats were aliquoted and stored in cryovials tubes at -
80 0C. Upon completion of sample collection, these samples were then transferred to the Staten 
Serum Institut (SSI) in Copenhagen, Denmark in a 4 0C ice box in a period of 48 hours. Transfer of 
samples to Copenhagen were in accordance with the international standards (appendix 6).  At the 




2.4.1 Principles of multiplex analysis 
 
A commercially available 10 plex diabetes kit was used to determine the levels of adipokines in all 
study groups. The 10 plex diabetes kit was used to perform a luminex technique that works in a 
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flowmetric manner and is based on microspheres/beads that (5,6μm in diameter) act as a solid 
support for the luminex reactions. Bio-plex assays are referred to as bead-based multiplex assays 
which allows the measurement of diabetes biomarkers in various matrices including serum, plasma 
and culture supernatant (www.bio-rad.com/bio-plex). Circulating proteins are used as biomarkers 
for Bio-plex and are involved in the regulation of digestion and glucose metabolism. The 
multiplexing feature makes it possible to quantify the levels of multiple diabetes markers in a 
single well of a 96-well microplate in just 4 hours, using as little as 12.5μl of serum or plasma 
samples, or 50 μl of tissue culture supernatant (www.bio-rad.com/bio-plex). The principles of the 
Bioplex diabetes assays are otherwise the same as with ELISA, and it can be used for direct, 
indirect, competitive and sandwich immunoassays. This study used the sandwich immunoassay 
form of ELISA which involved coupling captured antibodies with the beads, incubating the beads 








2.4.2 Multiplex method 
 
The first step in the bio-plex assay preparation involved planning the plate layout which was 
followed by preparing the standards. The standards were prepared in a 1:4 dilution. For sample 
preparation, 20µl of the sample and 80µl of the assay diluent were mixed together to make a total 
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volume of 100µl (1:4 dilution ratio). The 20x coupled beads were vortexed for 30 seconds and 
diluted to 1x (288µl of beads and 5,472µl of assay buffer) in bioplex assay buffer. The diluted 
standards, samples, beads and controls were then equilibrated at room temperature for 20 min 
before use.  
 
The 96-well filter plate was pre-wetted with 100μl bioplex assay buffer. The diluted beads were 
vortexed for 10-20 seconds prior to adding 50µl of the beads to each well of the assay plate. The 
assay plate was then washed three times with 100µl of the bioplex wash buffer. The diluted 
standards, samples and controls were vortexed before adding 50µl to each well (changing the pipet 
tip after every volume transfer) of the assay plate. This was followed by covering the plate with a 
sealing tape and then incubating it on a shaker at 850+/- 50 rmp at room temperature for 1 hour. 
While the samples were incubating, the 20x detection antibody was vortexed for 30 sec and 
rapidly-spun prior to pipetting in order to collect the entire required volume at the bottom of the 
vial. The 20x detection antibody was diluted to 1x by mixing 300µl of 20x detection antibody with 
2700µl of detection antibody diluent to make a sufficient volume (3000µl) of detection antibody.   
 
After incubating the samples, the sealing tape was removed slowly and the plate was placed onto a 
magnetic plate and thereafter supernatant was discarded by inversion. Thereafter, the plate was 
rinsed 3 times with 100µl of the Bioplex wash buffer. Detection antibody (25μl) was then added 
gently to each well and the plate was incubated for 30 min on a shaker at 850+/- 50 rmp at room 
temperature.  
 
While the detection antibody was incubating with 10 minutes left to incubation time, a quick-spin 
centrifugation of the streptavidin-PE (100x) was performed prior to pipetting in order to collect the 
entire volume at the bottom of the vial. A sufficient volume of streptavidin-PE (1x) was prepared 
by mixing 60µl of 100x streptavidin-PE and 5940µl assay buffer and then covered with aluminium 
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foil in order to protect from sunlight.  After the detection antibody incubation, the sealing tape was 
slowly removed, the magnetic plate attached, and supernatant discarded. The plate was then 
washed 3 times with 100µl of the Bioplex wash buffer. This was followed by addition of 50μl 
streptavidin-PE (1x) to each well, the plate was then covered with foil and incubated for 10 
minutes. After the streptavidin-PE incubation, the sealing tape was removed before reading the 
plate using a Bioplex MAGPIX instrument which was prepared 30 minutes prior to use.  
 
The results obtained were exported to excel to be analysed. Measurements and data analysis of all 
assays were performed on the Bioplex system in combination with Bioplex manager software 
version 4.1.1 using 5-parametric curve fitting (Bio-Rad). 
 
2.5 Data analysis 
 
Graph Pad Prism (version 6) was used to analyse the data. To assess the normality distribution of 
data, the Shapiro-Wilk test was performed. To analyse non-normal data, we used non-parametric 
tests (Kruskal Wallis H test and Mann-Whitney U test) and to analyse normal distributed data, we 
used parametric tests (Analysis of variance test (ANOVA) and independent samples t-test). A p 















































































3.1 Demographic and clinical data of patients 
 
The study population consisted of 30% non-pregnant, 40% normotensive pregnant and 30% pre-eclamptic 
women, equally stratified for HIV status.  With regards HIV status, the study population comprised 45% HIV 
positive and 55% HIV negative women. The pre-eclamptic group was stratified into early and late onset pre-
eclampsia. The patient demographics are displayed in Table 1 below as mean and standard deviations
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Table 3.1: Clinical demographics of adipokines across the study groups (stratified by HIV status) of 
pregnant and non-pregnant women. Clinical demographics values are shown as amedian and 

















75.00 (65-82.75) 69 (63.13-83.15) 78.25(69.75-97.70) 
Systolic Blood Pressure 
(mmHg)a 
119 (112-127) 121 (110-128) 168 (161.3-178.8) 161 (151-171.5) 
Diastolic Blood Pressure 
(mmHg)a 
74.50 (65-80) 73 (68-80) 104 (95.25-114.8) 101 (94.50-108) 





29.50 (26.15-33.33) 28.59 (25.42-35.40) 31.61 (27.10-36.88) 
Gestational age 
(weeks)a 
- 39 (38-40) 31 (27.75-35.25) 37 (34-38) 
Baby weight 
(kg)a 
- 3.2 (2.99-3.57) 1.4 (1.01-1.920) 2.87 (2.4-3.12) 
Placental weight 
(g)b 
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Table 3.2: Patient clinical demographics across the study population stratified by HIV status. Clinical demographics values are shown as amedian and 
interquartile range and as bmean and standard deviations. 
 
 





















73 (64-86.25) 76.00 (68-86.90 70.60 (64.75-80) 68.50 (62.70-
82.10) 










179.5) 171 (163-178) 
164.5 (156.5-




75 (64-78) 74 (63-81.50) 75 (66-82) 72.50 (69-78) 104 (93.50-
113.5) 





























---- --- 3.250 (3-3.655) 3.2 (2.97-3.47) 1.51 (1.193-
2.423) 
1.33 (0.93-1.8) 3 (5.545-3.250) 2.6 (2.24-3.050) 
Placental weight 
(g)b 
--- --- 628±98.24 612.5±90.35 492.3±236.2 416.7±138.9 666.3±164.5 557.3±127.1 
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Table 3.3: Analysis of clinical demographics across study groups. Statistical test used; aMann Whitney U test (U and p value) and bindependent t-test (t and p 
value). Values highlighted in red indicate significant difference. 
 Normotensive Vs 
Non-pregnant 
Normotensive Vs 
Early onset PE 
Normotensive Vs 
Late onset PE 
Non-pregnant Vs 
Early onset PE 
Non-pregnant Vs 
Late onset PE 
Early onset Vs Late 
onset PE 
Age (years)b 8.337 (p<0.001) 2.271 (p<0.05) 0.3216 (p>0.05) 3.326 (p>0.05) 6.491 (p<0.001) 6.491 (p<0.001) 
Weight (kg)a 5187 (p>0.05) 1770 (p>0.05) 2861 (p<0.05) 1293 (p>0.05) 2257 (p>0.05) 700.5 (p>0.05) 
BMI (kg/m2)a 5240 (p>0.05) 1867 (p>0.05) 2992 (p>0.05) 1354 (p>0.05) 2341 (p>0.05) 788 (p>0.05) 
Systolic BP (mmHg)a 5156 (p>0.05) 20 (p<0.001) 70.50 (p<0.001) 19 (p<0.001) 51 (p<0.001) 705.5 (p>0.05) 
Diastolic BP 
(mmHg)a 
5231 (p>0.05) 130 (p<0.001) 271 (p<0.001) 91 (p<0.001) 180.5  (p<0.001) 819 (p>0.05) 
CD4 (cells/mm3)b 0.6197 (p>0.05) 1.397 (p>0.05) 0.04627 (p>0.05) 1.015 (p>0.05) 0.3658 (p>0.05) 1.401 (p>0.05) 
GA (weeks)a --- 292.5 (p<0.001) 1136 (p<0.001) --- --- 286.5 (p<0.001) 
Baby weight (Kg)a --- 125.5 (p<0.001) 1826 (p<0.001) --- --- 228 (p<0.001) 
Placental weight (g)b --- 5.822 (p>0.05) 0.1526 (p>0.05) --- --- 3.488 (p<0.001) 
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Table 3.4: Analysis of patient clinical data in study groups stratified by HIV status. Statistical test 
used; aMann Whitney U test (U and p value) and bindependent t-test (t and p value). Values 
highlighted in red indicate significant difference. 
 
 Non-pregnant Normotensive Early onset PE Late Onset PE 
Age (years)b 2.175 (p<0.05) 3.217 (p<0.01) 0.719 (p>0.05) 1.315 (p>0.05) 
Weight (Kg)a 948.5 (p>0.05) 1367 (p<0.05) 119.5 (p>0.05) 352.5 (p>0.05) 
BMI (kg/m2)a 904.5 (p>0.05) 1369 (p<0.05) 104 (p>0.05) 330 (p>0.05) 
Systolic blood 
pressure (mmHg)a 
940 (p>0.05) 1485(p>0.05) 124 (p>0.05) 294.5 (p>0.05) 
Diastolic blood 
pressure (mmHg)a 
960.5 (p>0.05) 1633 (p>0.05) 108 (p>0.05) 297 (p>0.05) 
Gestational age 
(weeks)a 
--- 1561 (p>0.05) 77 (p>0.05) 198 (p>0.05) 
Baby weight (kg)a --- 1481 (p>0.05) 87.50 (p>0.05) 260.5 (p>0.05) 
Placenta weight 
(g)b 




3.1.1 Maternal age 
 
The mean age± standard deviation was 33.10 ± 7.47 years, 25.59 ± 5.63 years, 28.19 ± 6.30 years and 
25.28 ± 5.98 years in the non-pregnant, normotensive pregnant, early-onset pre-eclamptic and the 
late-onset pre-eclamptic groups respectively. Maternal age ranged from 18-45 years across all the 
study groups. 
 
The Shapiro-Wilks test revealed that the distribution of maternal age was normally distributed hence a 
parametric one-way analysis of variance (ANOVA) test was used to analyse maternal age across 
study groups. Based on HIV status, there was a significant difference in maternal age across the study 
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categories (F (3.292) = 28.23, p< 0.001; Figure 3.1). A multiple comparison Tukey Honest significant 
difference (HSD) test indicated that the non-pregnant, normotensive and late-onset group were older 
in the HIV positive group compared to their corresponding HIV negative group (Figure 3.2). In 
contrast, the early onset pre-eclamptic HIV positive group were younger than their corresponding 
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p < 0 .0 5
 
Figure 3.1: Age across study groups of pregnant and non-pregnant women. 
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3.1.2 Maternal weight 
 
The median maternal weight was 74.75kg (45-130kg). The Shapiro-Wilks test revealed that the 
distribution of maternal weight was not normally distributed hence non-parametric tests were used to 
assess the distribution of maternal weight across the study groups. A Kruskal-Wallis H test indicated 
no statistical significant in the distribution of maternal weight amongst the study groups (χ2 (3)=5.245; 
p >0.05). However, a non-parametric Mann-Whitney U test found that there was a significance effect 
of HIV status on maternal weight across the study groups (U=1366.50, p<0.01). The test revealed that 
within the normotensive group, maternal weight was higher in the HIV negative group compared to 
HIV positive group. 
 
 
3.1.3 Gestational age (GA) 
 
Gestational age was not normally distributed amongst study groups. A Kruskal-Wallis H test revealed 
that there was a significant difference amongst the study groups (χ2(3)= 67.54; p<0.001; Figure 3.3).  
The Mann-Whitney U test revealed no significant effect of HIV status on gestational age. Gestational 
age was higher in the normotensive compared to the non-pregnant group. Similarly gestational age 
was higher in the non-pregnant compared to the early-onset pre-eclamptic group. Additionally, GA 
was significantly higher in the normotensive compared to the early-onset (U=292.50; p<0.001) and 
late-onset pre-eclamptic group (U=2861.00; p<0.001) 
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Figure 3.4: Gestational age in study groups subdivided by HIV status. 
 
3.1.4 Maternal Blood Pressure 
 3.1.4.1 Systolic pressure 
 
The medians and IQR of systolic blood pressure is displayed on table 3.1 and 3.2. A Shapiro-Wilks 
test indicated that systolic blood pressure did not follow a normal distribution. Both log and square 
root transformation did not normalise the data hence non-parametric tests were used.  A Kruskal-
Wallis H test indicated that there was a significant difference in systolic blood pressure between the 
study groups (χ2(3)= 182.36; p<0.001). The Mann-Whitney U test showed a statistical significant 
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Systolic blood pressure was elevated in the early-onset (U=19.00; p<0.001) and late-onset (U=180.50; 
p<0.001) compared to the non-pregnant group. Furthermore, systolic blood pressure was significantly 
higher in the late-onset pre-eclamptic compared to the normotensive group which had a mean rank of 
60.59; (U=70.50; p<0.001). Additionally, there was a significant difference in the early-onset pre-
eclamptic versus normotensive groups (U=20.00; p<0.001).  
 
3.1.4.2 Diastolic pressure 
 
Medians and IQR of diastolic blood pressure are displayed on table 3.1 and 3.2. A Shapiro-Wilks test 
indicated that diastolic blood pressure did not follow a normal distribution; hence non-parametric tests 
were used for analysis.  The Kruskal-Wallis H test indicated that there was a significance difference in 
diastolic blood pressure across all study groups (χ2(3)=183.36; p<0.001). The Mann-Whitney U test 
revealed no effect of HIV status on diastolic blood pressure. Of note, the test revealed that diastolic 
blood pressure was elevated in the early (U=130; p<0.001) and late-onset pre-eclamptic groups (U= 
271.00; p<0.001) compared to the non-pregnant group. Additionally, systolic blood pressure was 
significantly higher in the late-onset pre-eclamptic compared to the normotensive groups (U=70.50; 
p<0.001). Additionally, systolic blood pressure was elevated in the early-onset pre-eclamptic 
compared to the normotensive groups (U=20.00; p<0.001). 
 
3.1.5 Body mass index  
 
Body mass index (BMI) per group was not normally distributed. A Kruskal-Wallis test showed no 
significance difference in BMI amongst the groups (χ2(3)=2.89; p>0.05). A pair-wise comparison 
Mann-Whitney U test revealed a significantly higher BMI in the normotensive HIV negative  
 Compared to the normotensive HIV positive group (U=1379.00; p<0.01).  
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3.1.6 Further analysis of clinical demographics 
 
3.1.6.1 Indication for delivery 
 
Within the pregnant groups (normotensive and pre-eclamptic), 65.9% of deliveries were performed in 
the interest of the baby compared to maternal indications. The Pearson Chi-square test showed a 
statistical significant difference between the normotensive and pre-eclamptic groups (p<0.001). Forty 
five percent pregnant women delivered by caesarean sections (C-section), whilst 27% required 
emergency C-section. Induction of labour was required in 4.6% of pregnant women whilst only 23% 
had a natural birth.  
 
3.2.6.2 Clinical complications encountered 
 
Moreover, clinical complications encountered in our study included a case of abruption placentae, 9 
cases of eclampsia, 5 cases of imminent eclampsia and 12 cases of severe pre-eclampsia. 
Additionally, there were 6 cases of still-births.  
 
3.1.7 Baby weight 
 
Baby weights were not normally distributed amongst the study groups. A Kruskal-Wallis H test 
indicated a significant difference in baby weight across study groups (χ2(2)=15.801; p<0.001; Figure 
3.5). Additionally, the Mann-Whitney U test indicated no significant effect of HIV status on baby 
weight. However, the effect of pregnancy type (normotensive pregnant versus pre-eclamptic) on baby 
weight was statistical significant.  Baby weight was lower in the pre-eclamptic group compared to the 
normotensive group. Additionally, within the pre-eclamptic group, babies of early onset women 
weighed more compared to babies of late onset pre-eclamptic women (U=228; p<0.001; Figure 3.6).  
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Figure 3.5: Baby weight (Kg) across the pregnant study groups 
 
 


















































































Figure 3.6: Baby weight (kg) across the pregnant study groups stratified by HIV status 
 
 
3.1.8 Placental weight 
 
One-way ANOVA showed a significance difference in placental weight across study groups (F 
(2.173) = 15.15; p<0.001). A multiple comparisons Tukey HSD test further revealed a significance 
difference in placental weight between normotensive HIV negative versus early onset HIV negative 
(p<0.01) and early onset HIV positive (p<0.001) groups. Additionally, there was a significant 
difference in placental weight between normotensive HIV positive versus early onset HIV negative 
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(p<0.05) and early onset pre-eclamptic HIV positive (p<0.001) women. Also, there was a significant 
difference between the early-onset pre-eclamptic HIV negative versus late-onset pre-eclamptic HIV 
positive (p<0.001), early-onset pre-eclamptic HIV negative versus late onset pre-eclamptic HIV 
negative (p<0.001) and late-onset pre-eclamptic HIV positive versus late-onset pre-eclamptic HIV 
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3.2 Analysis of adipokines 
 
Adipokine levels of C-peptide, ghrelin, gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 
(GLP-1), glucagon, insulin, plasminogen activator inhibitor (PAI)-1 and visfatin are outlined in 
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Table 3.5: Adipokine levels across study groups, values are shown as medians and interquartile ranges (IQR). Kruskal Wallis H test was used, values 















C-peptide 206 (32-363) 141.9 (94.7-79.5) 264.5 (104-379.1) 241.1 (116.520.2) p< 0.01 
Ghrelin 264.1 (102.9-428.3) 230.6 (98.70-375.2) 185.2 (74.31-366.3) 227 (86.42-358.2) p>0.05 
GIP 21.62 (10.84-53.31) 15.64 (5.19-37.47) 30.5 (12.32-66.3) 20.94 (15.26-44.78) P<0.01 
GLP-1 94 (75.31-116.4) 75.31 (21.01-115.3) 94 (75.31-116.4) 94 (21.01-115.3) P<0.05  
Glucagon 47.93 (41.94-55.83) 47.93 (9.92-49.39) 47.93 (41.94-55.83) 47.93 (9.92-49.39) p>0.05 
Insulin 141.9 (39.54-271.6) 74.26 (25.11-177.7) 103.7 (34.7-558.6) 74.5 (36.27-284.7) p>0.05 
PAI-1 5219 (311.6-15506) 6458 (1820-13695) 6661 (2077-15265) 6975 (573.6-148.95) p>0.05 
Visfatin 555.4 (153.7-5802) 744.4 (310.4-8233) 886.2 (262.1-6981) 2800 (487.5-10568) P<0.05 
 




Table 3.6: Adipokine levels across study groups based on HIV status (results are shown as median and interquartile range). Kruskal Wallis H test was used. 
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Table 3.7: Pairwise comparison/analysis of adipokines across stud groups. Statistical test used; Mann Whitney U test was used. Values in red=significant 
difference. 
 Normotensive Vs 
Non-pregnant 
Normotensive Vs 
Early onset PE 
Normotensive Vs 
Late onset PE 
Non-pregnant Vs 
Early onset PE 
Non-pregnant Vs 
Late onset PE 
Early onset Vs Late 
onset PE 
C-peptide 4169 (p<0.01) 1597 (p>0.05) 2640 (p<0.01) 1353 (p>0.05) 2505 (p>0.05) 847 (p>0.05) 
Ghrelin 5041 (p>0.05) 1727 (p>0.05) 3180 (p>0.05) 1197 (p>0.05) 2164 (p>0.05) 918.5 (p>0.05) 
GIP 4151 (p<0.01) 1435 (p<0.05) 2614 (p<0.01) 1355 (p>0.05) 2573 (p>0.05) 892.5 (p>0.05) 
GLP-1 4302 (p<0.01) 1539 (p>0.05) 3312 (p>0.05) 1424 (p>0.05) 2206 (p>0.05) 784.5 (p>0.05) 
Glucagon 4415 (p<0.05) 1626 (p>0.05) 3394 (p>0.05) 1416 (p>0.05) 2173 (p>0.05) 795 (p>0.05) 
Insulin 4328 (p<0.05) 1543 (p>0.05) 3145 (p>0.05) 1398 (p>0.05) 2413 (p>0.05) 842 (p>0.05) 
PAI-1 5061 (p>0.05) 1921 (p>0.05) 3434 (p>0.05) 1334 (p>0.05) 2505 (p>0.05) 914.5 (p>0.05) 
Visfatin 4532 (p<0.05) 1901 (p>0.05) 2964 (p<0.05) 1195 (p>0.05) 1806 (p<0.01) 785.5 (p>0.05) 
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Table 3.8: Analysis of adipokines in groups stratified by HIV status. Mann Whitney U test was used 
for pairwise comparison of the subgroups. Values highlighted in red indicate significant difference. 
 Non-pregnant Normotensive Early onset PE Late Onset PE 
C-peptide 995 (p>0.05) 1556 (p>0.05) 101 (p>0.05) 376 (p>0.05) 
Ghrelin 902 (p>0.05) 1797 (p>0.05) 94 (p>0.05) 360(p>0.05) 
GIP 947.5 (p>0.05) 1591 (p>0.05) 80.50 (p>0.05) 328 (p>0.05) 
GLP-1 688 (p<0.05) 1694 (p>0.05) 112 (p>0.05) 356.5 (p>0.05) 
Glucagon 924 (p>0.05) 1679 (p>0.05) 95 (p>0.05) 357.5 (p>0.05) 
Insulin 1001 (p>0.05) 1552 (p>0.05) 106 (p>0.05) 367.5 (p>0.05) 
PAI-1 818 (p>0.05) 1713 (p>0.05) 122 (p>0.05) 368.5 (p>0.05) 



















A Kruskal Wallis H test showed a difference in the level of c-peptide across all study groups 
(χ²(3)=11.71; p<0.01; Figure 3.7), additionally, the Dunn’s multiple comparison test showed a 
difference between the non-pregnant versus normotensive and the normotensive versus late onset 
group. A Mann-Whitney U test found a significant difference between the non-pregnant and 
normotensive (p=0.01), and between the normotensive and the late onset group (p=0.01). There were 
no significant differences in the other groups. When considering HIV status, the Kruskal Wallis H test 
revealed that there was no significant differences in the levels of c-peptide amongst the groups 
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Figure 3.7: C-peptide across study groups. C-peptide is elevated in the early onset when comparing to 
the other groups, followed by late onset, non-pregnant and normotensive groups.  
 




Figure 3.8: C-peptide across sub-stratified by HIV status. In the non-pregnant and normotensive, c-
peptide is lower in the HIV negative groups compared to the HIV positive groups. Whilst, in the pre-













































































































The medians and interquartile range of ghrelin are displayed on Table 3.5 and 3.6. The Kruskal Wallis 
H test showed no statistical differences in the levels of ghrelin across study groups (p>0.05; Figure 
3.9). Also, the Dunn’s multiple comparison test indicated no statistical difference among the groups. 
Furthermore, HIV status had no effect on ghrelin levels across study groups (p>0.05; Figure 3.10). 
 
Figure 3.9: Levels of ghrelin across categories of study groups. The non-pregnant has the highest 
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Figure 3.10: Levels of ghrelin in study groups sub-stratified by HIV status. Ghrelin was elevated in 
the HIV positive non-pregnant and early onset groups compared to the HIV negative groups, whilst it 
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3.2.3 Gastric inhibitory polypeptide 
 
The median (IQR) for GIP are outlined on Tables 3.5 and 3.6. The Kruskal-Wallis H test and the 
Dunn’s multiple comparison test found a statistical significant difference in GIP across the study 
groups (p<0.01; Figure 3.11). Furthermore, a pairwise comparison test found a significant difference 
between the non-pregnant versus normotensive (p<0.01); normotensive versus early onset (p<0.05; 
Figure 3.11) and normotensive versus the late onset group (p<0.01). 
 
When considering HIV status, the Kruskal Wallis-H test revealed a statistical difference across the 
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3.2.4 Glucagon-like peptide 1 
 
The median and IQR for GLP-1 are displayed on Tables 3.5 and 3.6. The data for GLP-1 was not 
normally distributed hence we performed a non-parametric test. The Kruskal-Wallis H test and the 
Dunn’s multiple comparison test found a significant difference in GLP-1 across the study groups 
(p<0.05; Figure 3.13). Furthermore, a Mann Whitney U test found a significant difference between 
non-pregnant versus normotensive (p<0.01).  
 
When considering HIV status, the Kruskal Wallis-H test revealed a statistical difference across the 
study groups (p<0.05; Figure 3.14). Additionally, the Mann Whitney U test showed a significant 
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Figure 3.13: Levels of GLP-1 across categories of study groups. The levels of GLP-1 were lowest in 
the normotensive group.  
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Figure 3.14: Levels of GLP-1 across study groups stratified by HIV status. There seem to be no 


















The median and IQR for glucagon are displayed on Tables 3.5 and 3.6. Glucagon was not normally 
distributed hence we performed a non-parametric test. The Kruskal-Wallis H test and the Dunn’s 
multiple comparison test found no significant difference in the levels of glucagon across the study 
groups (p>0.05; Figure 3.15). However, when performing a Mann Whitney U test, we found a 
significant difference between the non-pregnant and normotensive group (p<0.05). 
 
When considering HIV status, the Kruskal Wallis-H test indicated that HIV status does not affect 
glucagon levels (p>0.05; Figure 3.16). However, a Mann-Whitney U test found a significant 
difference between HIV positive non-pregnant and HIV negative non-pregnant (p<0.05). 
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Figure 3.16: Glucagon levels in study groups based on HIV status. The non-pregnant and early onset 


















The median and IQR for insulin are displayed on Tables 3.5 and 3.6. The Kruskal-Wallis H test and 
the Dunn’s multiple comparison test found no significant difference in the levels of insulin across the 
study groups (p>0.05; Figure 3.17). However, a Mann Whitney U test, found a significant difference 
between the non-pregnant and normotensive group (p<0.05). 
 
When considering HIV status, the Kruskal Wallis-H test revealed a statistical difference across the 
study groups (p>0.05; Figure 3.18). 
 
Figure 3.17: Insulin levels across study groups. The non-pregnant group have high levels of insulin 
compared to the pregnant groups, however, in the pregnant groups; the early onset has elevated levels 
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Figure 3.18: Insulin levels across categories of study groups stratified by HIV status. In the pre-
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3.2.7 Plasminogen activator inhibitor-1 
 
The median and IQR for plasminogen activator inhibitor (PAI)-1 are displayed on Tables 3.5 and 3.6. 
The Kruskal-Wallis H test and the Dunn’s multiple comparison test found no significant difference in 
the levels of PAI-1 across the study groups (p>0.05; Figure 3.19). Furthermore, Mann Whitney U test 
found no significant difference between the groups (p>0.05).  
When considering HIV status, the Kruskal Wallis-H test revealed no significant difference across the 
study groups (p>0.05; Figure 3.20). 
 
Figure 3.19: Levels of PAI-1 across study groups. The pregnant groups have the same levels of PAI-1, 
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The median and IQR of visfatin are displayed on Tables 3.5 and 3.6. The Kruskal-Wallis H test and 
the Dunn’s multiple comparison test found a significant difference in the levels of visfatin across the 
study groups (p<0.05; Figure 3.21). Additionally, a Mann-Whitney U test found a significant 
difference between the non-pregnant versus normotensive group (p<0.05) and the late onset versus the 
non-pregnant group (p<0.01). 
 
When considering HIV status, the Kruskal Wallis-H test revealed a statistical difference across the 
study groups (p<0.05; Figure 3.22). A Mann-Whitney U test revealed that there is a significant 
difference between the HIV positive versus negative non-pregnant groups (p<0.05). 
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Figure 3.22: Visfatin across study groups stratified by HIV status. The pre-eclamptic and non-
pregnant groups, the HIV positive groups have elevated levels of visfatin compared to the HIV 
negative. 
 
Figure 3.21: Levels of visfatin across study groups. Visfatin is elevated in the pre-eclamptic groups 
when comparing to the non-pregnant and the normotensive group. 
 
 




























The millennium goal (1999) was developed to reduce maternal deaths by 75% by the year 2015.  
Since its establishment, maternal mortality has decreased by 50% (MDG Report, 2015). Sadly, a 
similar decline of maternal mortality cannot be reported for developing countries, especially the 
countries in the sub-Saharan region. In South Africa, despite a 50% decrease in maternal deaths for 
the period 2000-2015, maternal death is a still a major health burden. The latest Saving Mothers 
report indicates that the top 3 causes of maternal death are non-pregnancy related infections (HIV, TB 
and pneumonia), 38% and obstetric haemorrhage (16%) and hypertension (14%) of all maternal 
deaths. Pre-eclampsia, accounts for 83% of deaths emanating from hypertension in pregnancy. 
 
In South Africa, the national HIV prevalence amongst women has decreased from 30.2% to 29.1% 
(Udjo, 2006). Notably, the HIV epidemic has devastating consequences on women of reproductive 
age 15 - 24 years (Moodley and Moodley, 2005). Approximately 30% of South African parturients are 
co-infected with HIV (Kalumba et al., 2013). The administration of ART to all HIV positive pregnant 
women with CD4 counts<400 has contributed to a decrease in neonatal and maternal deaths.   
 
Globally, more than one billion people are overweight or obese (Obesity Task Force, 2005).  South 
Africa is facing a new dilemma in that it is ranked as the third highest country in the world with 
obesity. In pregnancy, obese women have increased risk of suffering from complications due to 
caesarean section, sepsis, haemorrhage etc.  
 
This study reports on adipokine dysregulation in the co-localisation of the three conditions (HIV, pre-
eclampsia and obesity). 
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4.1. Maternal demographics 
 
4.1.1 Maternal age 
 
In this study the mean age± standard deviation was 33.10 ± 7.47 years, 25.59 ± 5.63 years, 28.19 ± 
6.30 years and 25.28 ± 5.98 years in the non-pregnant, normotensive pregnant, early-onset pre-
eclamptic and the late-onset pre-eclamptic groups respectively. These maternal ages supports global 
trends of women delaying their first pregnancy (Benzies, 2008). Advanced maternal age has an 
increased risk of gestational diabetes (Jacobsson B, 2004) placenta previa (Jolly M et al., 2000), 
preeclampsia (Ozalp et al., 2003), miscarriage (Goldman et al., 2005), pregnancy-induced 
hypertension and the need for caesarean deliveries (Lamminpää et al., 2012). 
 
We report that based on HIV status, there was a significant difference in maternal age across the study 
categories (p< 0.001) and that the non-pregnant, normotensive and late-onset group were older in the 
HIV positive group compared to their corresponding HIV negative group. The distribution of HIV 
according to age demonstrates that the HIV positive participants tended to be older than the HIV 
negative participants. This attests to the fact that local incidence of the HIV disease seems to be 
stabilizing, as supported by local statistics (Lehola, 2014). In contrast, the early onset pre-eclamptic 
HIV positive group were younger than their corresponding HIV negative group. Maternal age appears 
to be independent obstetric risk factor for early onset of preeclampsia and impaired fetal growth 
(Lamminpää et al., 2012).  The young participants in our EOPE cohort is supported by classical risk 
factors such as nulliparity (Walsh, 2007; Luo et al., 2007), Black ethnicity (ACOG Practice 
Guideline, 2002) and primipaternity (ACOG Practice Guideline, 2002; Zhang et al., 1997), all of 
which are risk factors for pre-eclampsia development. The maternal age of the normotensive pregnant 
cohort in our study was similar to that of previous studies (Aksornphusitaphong & Phupong, 2013). 
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4.1.2 Maternal weight 
The results of this study shows no statistical significant in the distribution of maternal weight amongst 
the study groups.  Obesity is belied to increase the incidence of preeclampsia via an increased insulin 
resistance or inflammation (Walsh, 2007). Insulin resistance is associated with endothelial 
dysfunction and increased secretion of endothelin 1, a potent vasoconstrictor (Marasciulo et al., 
2006). We however, did not notice a correlation of increased maternal weight with pre-eclampsia 
development. A limitation of our study is that we do not have pre-pregnancy weight across all 
pregnant study groups. 
 
We report a significance effect of HIV status on maternal weight across the study groups (p<0.05). 
Within the normotensive group, maternal weight was higher in the HIV negative group compared to 
HIV positive group.  It is well documented that HIV infection results in wasting, generalised loss of 
fat-free and fat mass, augmenting morbidity and mortality (Macallan, 1999). An optimum maternal 
weight during pregnancy is important for optimal foetal development. An inadequate weight gain is 
associated with intrauterine growth retardation and perinatal mortality (World Health Organisation 
Report., 2005). Additionally, HIV-positive women in developing countries (like South Africa) are 
vulnerable to dietary deficiencies from insufficient dietary intake and HIV infection to meet the 
nutritional load of pregnancy (Brocklehurst P and French R, 1998; Scholl  & Johnson, 2000). 
 
4.1.3 Body Mass Index 
In our study there was no significance difference in BMI amongst the study group. There was a 
significantly higher BMI in the normotensive HIV negative compared to the normotensive HIV 
positive group (p<0.01). In this study, BMI was calculated in the third trimester of pregnancy. BMI is 
based on population and ethnicity specific charts. A baseline pregnancy BMI has only recently been 
outlined for our Black ethnic group within KwaZulu-Natal, South Africa and are congruent with this 
study due to use of same patient intake (Govender, 2014).  
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The relationship between BMI and hypertension in sub-populations of Ethiopian, Vietnamese and 
Indonesian population has been investigated (Tesfaye et al., 2006). In our study, the comparison 
between the pregnant cohorts allowed for a more uniform comparison, however the majority of the 
participants fell into the overweight, pre-obese and grade 1 obesity category. It is also plausible to link 
the finding of similar BMI amongst the normotensive and pre-eclamptic cohorts in this study to a high 
pre-pregnancy weight. Pre-pregnancy weight was not available for the participants. A consideration of 
high pre-pregnancy weight is conceivable since 70 % of South African women are considered 
overweight. Also a strong association between pre-eclampsia and high BMI has been reported 
(Duckitt, K & Harrington, 2005; Machado Elizabeth Stankiewicz et al., 2014). 
 
4.1.4 Blood pressure 
In our study, there was a higher blood pressure in the pre-eclamptic groups compared to the non-
pregnant and normotensive groups. Currently both the International Society for the Study of 
Hypertension in Pregnancy and the Working Group of the National High Blood Pressure Education 
Program in the United States both define pre-eclampsia as either systolic blood pressure ≥140 mm Hg 
or diastolic blood pressure ≥90 mm Hg, with associated proteinuria after 20 weeks’ gestation (Brown 
et al., 2001, 2000).  
 
We also report a significantly higher systolic and diastolic blood pressure in our pre-eclamptic cohort 
compared to the normotensive non-pregnant and normotensive pregnant population.  Furthermore, we 
found that a significant difference with respect to HIV status and blood pressure across the non-
pregnant, pre-eclamptic and normotensive cohorts (p<0.001). 
A posturing inspection of BP in this study revealed a trend towards a lower systolic and diastolic 
blood pressure in HIV naive individuals. This trend is in keeping with the development of insulin 
resistance, obesity and hypertension in HIV infection (Gazzaruso et al., 2003). Notably metabolic 
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syndromes such as obesity, impaired glucose tolerance, diabetes, hypertriglyceridemia, and reduced 
levels of high-density lipoprotein are risk factors for cardiovascular disease development, including 
blood pressure elevation (Hadigan et al., 2001; Samaras et al., 2007). 
 
4.1.5 Gestational Age 
In our study, gestational age was significantly different across the study groups (p<0.001). Gestational 
age was higher in the normotensive compared to the early-onset (p<0.001) and late-onset pre-
eclamptic group (p<0.001). Our results are congruent with the classical theory in that pre-eclampsia is 
associated with lower gestational age. However, the converse has been demonstrated in that babies 
born to mothers with pre-eclampsia at term have fetal growth similar to that of babies born to 
normotensive mothers (Xiong et al., 1999). Also early-onset pre-eclampsia is associated with adverse 
perinatal outcomes, such as small for-gestational-age infants, than late onset pre-eclampsia due to 
inadequate placental blood flow (Van Rijn  et al., 2006). Moreover, placental lesions are higher the 
earlier the gestational age at the time of delivery, compared with normotensive control subjects 
(Moldenhauer  et al., 2003). 
 
Additionally, we report no significant effect of HIV status on gestational age in our study. In 2010, a 
study by Boyajian, reported to have found preterm birth did not differ between HIV positive women 
when compared to the negative women, however it found lower birth weight among babies born by 




In our study, baby weight was significant different across study groups (p<0.001). Baby weight was 
lower in the pre-eclamptic group compared to the normotensive group. Our results are supported by 
previous studies in that the mean birth weight of newborns and mean placental weight are 
significantly lower in pre-eclampsia than normotensive pregnancies (p<0.001) suggesting that 
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impaired placental function in preeclampsia is directly related to low placental and birth weights and 
poor fetal outcome (Kaur et al., 2013). However, in contrast to these findings, the birth weight of pre-
eclamptic women at term were found to be similar to that of babies born to normotensive mothers 
(Xiong et al., 2001), advocating against the reduced uteroplacental perfusion being the unique 
pathophysiologic process in pre-eclampsia. Our finding of low birth weight is in keeping with other 
studies, where babies from the EOPE cohort fell into the very low birth weight category (Kucukgoz 
Gulec et al., 2013, Lisonkova & Joseph, 2013).  
 
Our study also reports no significant effect of HIV status on baby weight across the study groups. In 
contrast to our study, a large scale Tanzanian study (2001) found that HIV positivity was not a risk 
factor for lower birth weight. Although earlier studies by Minkoff et al., (1990) found no association 
between HIV infection and risk for low birth weight, these were small studies. Notably they did not 
consider the stage of HIV disease (Minkoff et al., 1990). Likewise, later studies also did not show a 
correlation (Castetbon et al., 1999). In contrast, studies by Stratton et al., (1999) support the 
correlation of low birth weight with HIV infection (Stratton et al., 1999). 
 
Infant birth weight does not differ among women in the earlier stages of HIV disease, but has been 
shown to decrease significantly in stage III than in stage I infection (Dreyfuss et al., 2001). This may 
be attributed to the fact that with increased HIV infection, the immune system is further, down 
regulated eventuating in a deterioration of nutritional reserves. 
 
4.1.7 Placental weight 
In this study we observed a significant difference in placental weight across study groups (p<0.001). 
Supporting evidence is that the placental weight is has been previously reported to be significantly 
less in pre-eclampsia than normotensive pregnancies (Mallik et al., 1979; Udainia & Jain, 2001; 
Majumdar et al., 2005). Additionally, early onset pre-eclampsia is characterized by abnormal 
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placentation and resultant hypoxia. Poor fetal/neonatal outcomes particularly, lower birth weight and 
lower birthweight has been previously reported in the EOPE group (Lisonkova et al., 2013). The 
shallow placentation with resultant decreased blood flow and ensuing lower placental weight in the 
early onset pre-eclampsia group expounds placental inefficiency (Naicker et al., 2003).  
 
4.1.8 Mode of delivery 
Timing of delivery depends on several factors, including gestational age, fetal lung maturity, and most 
importantly, disease severity. In the pregnant groups (normotensive and pre-eclamptic) of our study, 
65.9% of deliveries were performed in the interest of the baby compared to maternal indications. In 
our study there was a significant difference between the normotensive and pre-eclamptic groups 
(p<0.001). Off note, pre-eclampsia may lead to significant fetal morbidity and mortality, including an 
increased incidence of placental abruption, fetal growth restriction, and preterm delivery (Turner, 
2010). In our study, forty five percent pregnant women delivered by caesarean sections (C-section), 
whilst 27% required emergency C-section. Induction of labour was required in 4.6% of pregnant 
women whilst only 23% had a natural birth. Moreover, clinical complications encountered in our 
study included a case of abruption placentae, 9 cases of eclampsia, 5 cases of imminent eclampsia and 
12 cases of severe pre-eclampsia. Additionally, there were 6 cases of still-births. In the early-onset 




In a study by Minire et al., (2013), maternal complications in pre-eclampsia were examined precisely 
and showed that liver damage occurred in 4.9% and 12.3% had renal impairment. Detachment of the 
placenta (abruption) was encountered in 7% of cases and 0.7% of patients had an epilepsy. HELLP 
syndrome was present only in 4.2%, pulmonary edema occurred in 5.6% of subjects, DIC was found 
in 2.8% of cases and only one patient (0.2%) was registered with encephalopathy (Minire et al., 
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2013). A limitation of this study is that the data on liver and renal function tests were not available for 
all participants hence it was not possible to speculate on the true incidence of liver and renal 
dysfunction in the local setting. This would have been an interesting area of future investigation, as 
there may be contributory disease to these organs with use of various antiretroviral drugs. 
 
4.1.10 HIV infection 
As per study design and inclusion criteria, forty five percent (45.1%) of our overall study population 
was HIV infected. It must be noted that the study was conducted at a large referral hospital, there is a 
higher number of HIV positive individuals in such a setting. Furthermore, in the Obstetric ward, a 
younger population tends to be the norm and this is a high risk group for the HIV infection. This study 
specifically included participants in the 18-45 years age group, an age group that carries the highest 
incidence of HIV nationwide (Lehola, 2014). As participants were of a similar age throughout the 
study groups their time of exposure to HIV infection may be similar. 
 
As the national government of South Africa had instituted policy at the time of initiation of this study, 
all pregnant women with a CD4 count less than 350 cells/mm3 commenced an ARV triple regimen 
therapy and those with a CD4 >350 received PMTC this may explain the significant difference in 





We report a significant difference in c-peptide levels across study groups (p<0.01). We also 
demonstrated a significant difference in c-peptide between the non-pregnant versus normotensive 
(p<0.01) and the normotensive versus late onset pre-eclamptic group (p<0.01). In addition to that, we 
have found that the levels of c-peptide are elevated in the pre-eclamptic groups when compared to 
normotensive pregnant and nom-pregnant groups. According to (Schipper et al., 2010), adipokines 
 
87 | P a g e  
 
play a huge role in the pathophysiology of obesity, which in turn plays a crucial role in pre-eclampsia 
development. Moreover, several studies have reported to have found a strong association between 
adipokines and pre-eclampsia development. This correlates with other studies that have reported that 
c-peptide plays a crucial role in glucose homeostasis since it is responsible for cleaving the A and B 
chain of pro-insulin. Additionally, insulin has been reported to be one of the most important 
adipokines that plays a role in the pathophysiology of pre-eclampsia by causing insulin resistance 
(Shangguan et al., 2009). Furthermore, pregnancy itself is a state of physiological insulin resistance, 
in pre-eclampsia, the levels of insulin are exaggerated. In contrast to our findings, serum C-peptide 
has been shown to be significantly lower in women with severe compared to mild pre-eclampsia and 
normotensive pregnant women (Sayed et al., 2015).  
 
When considering HIV status, there was no significant differences in the levels of c-peptide amongst 
the groups (p>0.05). Additionally, we found high levels of c-peptide in the HIV positive pre-
eclamptic groups. Our findings correspond with other studies that have reported high levels of 
adipokines in pregnant HIV positive women, owing to the fact that HIV does cause dysregulation of 
adipokines. Our results corresponds with the literature that has reported that HIV is characterized by 
changes in fat distribution and insulin resistance (Koutkia et al., 2003). Both HIV infection and its 
management therapies are known to contribute to metabolic and morphologic alterations that may 
increase risk dyslipidemia, altered glucose metabolism, central fat accumulation, and inflammation 
(Grunfeld et al., 2008). All three major classes of antiretroviral therapy (ART), including protease 
inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse 
transcriptase inhibitors (NNRTI), have been implicated in these complications, with the nature and 








In our study we with have found low levels of ghrelin in the pregnant groups, compared to the non-
pregnant. Ghrelin is a hormone that makes you want to eat, it is an antagonist of leptin. Both 
hormones play a role in energy homeostasis. In mid-pregnancy, ghrelin levels increase, but a later 
gestation, it is said that the levels of ghrelin decrease and then returns to normal after delivery 
(Fuglsang, 2008). 
 
Additionally, we found that HIV status does not impact levels of ghrelin. However the early onset 
pre-eclampsia has shown higher levels of ghrelin in the HIV positive group when comparing to the 
HIV negative group. According to Falasca and associates, HIV-related metabolic abnormalities 
include hypertriglyceridemia, hypercholesterolemia, insulin resistance, and diabetes mellitus (Falasca 
et al., 2006). Recent studies have reported that ghrelin plays a role in elevating hypertriglyceridemia 
promoting the deposition of triglycerides (TG) in the liver among HIV positive people (Falasca et al., 
2006).  
 
4.2.3 Gastric inhibitory polypeptide (GIP) 
 
We demonstrate a significant difference in GIP across the study groups (p<0.01). Furthermore, we 
also show a significant difference between the non-pregnant versus normotensive pregnant (p<0.01); 
normotensive pregnant versus early onset (p<0.05) and the normotensive pregnant versus the late 
onset pre-eclamptic group (p<0.01). Additionally, our study have found higher levels of GIP in pre-
eclamptic groups compared to normotensive pregnant groups. Studies done by Chen and associates 
have reported elevated levels of GIP in pregnancy when comparing to non-pregnant (Chen et al., 
1995). Furthermore, Studies have reported that adipokines are elevated in pregnancy and even more 
so in pre-eclampsia. 
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GIP was statistically different based on HIV status (p<0.001). Interestingly in fasting or 2-h glucose, 
insulin, pro-insulin and C-peptide concentration did not differ amongst antiretroviral naïve, on an 
ART regimen that contained an NNRTI but no protease inhibitors (PI),  on an ART regimen that 
included a PI but no NNRTI , on a non-PI/non-NNRTI containing regimen and a  HIV seronegative 
control groups (Grunfeld et al., 2008). All three major classes of antiretroviral therapy (ART), 
including protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and non-
nucleoside reverse transcriptase inhibitors (NNRTI), have been implicated in dyslipidemia, with the 
nature and magnitude of effects differing among drugs in a given class (Grunfeld et al., 2008). 
 
4.2.4 Glucagon-like peptide 1 (GLP-1) 
 
GLP-1 is a hormone that regulates glucose levels in the body by stimulating the secretion of insulin, 
and GLP-1 also inhibits appetite. In our study, we noted a significant difference in GLP-1 across the 
study groups (p<0.05) and between non-pregnant versus normotensive pregnant groups (p<0.01). 
GLP-1 is reduced by 25% among people with pre-diabetes and up to 20% among obese people 
compared to normal weight people. This specifies that the decrease in GLP-1 is not a result of type 2 
diabetes, but appears much earlier in the disease development and may dispose people to type 2 
diabetes development (Science Daily, 2015). Notably, the combined use of hormones glucagon and 
glucagon-like peptide 1 (GLP-1) may form the basis for a new treatment for obesity and diabetes in 
the future (Science Daily, 2013). GLP-1 promotes weight loss by central suppression of feeding and 
via delayed gastric emptying promoting early satiety (Näslund et al., 1999). A study by Bende and 
associates (2006) has reported that pregnancy does not alter secretion of incretin hormones. 
 
GLP-1 was statistically different based on HIV status (p<0.05) specifically, between the non-pregnant 
versus the normotensive groups (p<0.01). According to our knowledge, there is no literature reporting 
the association of GLP-1 and HIV. However, GLP-1 is involved in the secretion of insulin, and there 
have been several studies that have reported that HIV is associated with dysregulation of adipokines, 
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which can alter glucose homeostasis. It is therefore plausible to suggest that HIV does affect GLP-1 
levels. Additionally, HIV has been reported to be involved a number of chronic metabolic disorders of 
multifactoria which include increased prevalence of impaired glucose tolerance, diabetes mellitus 




We report no significant difference in glucagon across the study groups (p>0.05). Glucagon controls 
food intake and satiaty, through signaling the body to decrease levels of other appetite hormones like 
ghrelin (Science Daily, 2013). Glucagon induces the liver's production of glucose into the 
bloodstream and maintains the fuel supply for the brain. In this study, we found a significant 
difference between the non-pregnant and normotensive group (p<0.05). 
 
Also we show that HIV status does not affect glucagon levels (p>0.05). However, glucagon differed 
significantly between HIV positive non-pregnant versus HIV negative non-pregnant (p<0.05). 
Metabolic abnormalities (hyperlipidaemia and insulin resistance) and body fat redistribution (central 
adiposity and peripheral fat wasting) has been reported with increasing incidence in HIV-1 infected 
patients, receiving highly active antiretroviral therapies including HIV-1 protease inhibitors (Esteban 




Insulin blocks the secretion of glucagon, opposes glucagon action on the liver, and instructs the body 
to take up glucose from the blood (Science Daily, 2014). Glucagon and insulin normally counteract 
each other to stabilize blood-sugar levels. Glucagon is released by the pancreas in response to low 
concentrations of insulin and, conversely, glucagon release is suppressed by high levels of insulin in 
the bloodstream. In our study, we report no significant difference in insulin across the study groups 
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(p>0.05). However, we found a significant difference between the non-pregnant versus normotensive 
group (p<0.05).  
 
We have also found that HIV status did not affect insulin levels (p>0.05). Insulin plays a crucial role 
in glucose homeostasis by Insulin regulates how the body uses and stores glucose and fat. Many of the 
body's cells rely on insulin to take glucose from the blood for energy. In HIV positive individuals, 
Insulin ability to maintain glucose homeostasis is altered. Rondanelli and associates have reported that 
recently reported β cell dysfunction in HIV-infected individuals especially for individuals on anti-
retroviral treatment (Rondanelli et al., 2004).  
 
4.2.7 Plasminogen activator inhibitor (PAI)-1 
 
In our study, PAI-1 did not differ across the study groups (p>0.05) and between the groups (p>0.05).  
Significantly elevated levels of PAI-1 and fibronectin occurring early in pregnancies that 
subsequently develop pre-eclampsia suggest that these variables may have predictive values (Halligan 
et al., 1994). During pregnancy, profound changes take place in the hemostatic system, the levels of 
PAI-1 increases (Kruithof et al., 1987). The fibronolytic activity during pregnancy decreases, due to 
that fact that plasma levels of fibrinogen factor VII- VIII and von Willebrand factor increases. It is 
said that the decrease levels of fibrinolytic activity observed during pregnancy is due to increase 
levels of PAI-1 derived from the placenta (Kruithof et al., 1987). High levels of PAI-1 have been 
observed in pregnant women compared to non-pregnant women. A common deletion polymorphism 
that results in a sequence of 4G instead of 5G in the promoter region of the gene associated with small 
increase in the risk of venous thromboembolism (Said et al., 2012). Some studies have reported that 
this polymorphism is associated with adverse pregnancy outcome, however, the topic remains 
controversial. Moreover, a study by Linjen et al., (2005) reports that PAI-1 levels correlate with 
insulin resistance, can be used to predict the development of type 2 diabetes independently of other 
known risk factors (Linjen et al., 20015; Festa et al., 2002). 
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In our study, when considering HIV status, there was no effect on PAI-1 (p> 0.05). In HIV-associated 
lipodystrophy PAI-1 is augmented via dysregulation of the TNF-system (high TNF alpha and high 
sTNFR1) may play a role in up-regulating PAI-1 (He et al., 2005). In contrast, no association between 
PAI-1 levels with HIV or HCV (Keifer et al., 2013), whilst an association between worsening HIV 




We observed a significant difference in the levels of visfatin across the study groups (p<0.05) and 
between the non-pregnant versus normotensive pregnant group (p<0.05) and the late onset pre-
eclamptic versus the non-pregnant group (p<0.01). Maternal plasma visfatin peaks between 19–26 
gestational weeks in normal weight pregnant women (Mazaki-Tovi et al., 2009). There are only a few 
reports regarding circulating visfatin concentrations in pregnant women (Chan et al., 2006; Fasshauer 
et al., 2008). Indeed, only a single study reported the results of comparison of maternal visfatin 
concentrations between the three trimesters of pregnancy (Mastorakos  et al., 2007) and none included 
a comparison of circulating maternal visfatin concentrations between normal and overweight pregnant 
women. Given the diabetogenic effect of visfatin, it is tempting to suggest that the median visfatin 
concentration increase during pregnancy in association with insulin resistance and the increase in 
maternal weight. 
In our study there was no effect of HIV status on the level of visfatin across the study groups 
(p<0.05). There was a significant difference between the HIV positive versus negative non-pregnant 
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4.3 Obesity and pre-eclampsia 
 
Several studies have reported a strong association between insulin resistance and elevation of 
adipokines during pregnancy. A number of studies have analysed the association of obesity and the 
development of diabetes type 2. Women who are develop gestational diabetes are at high risk of 
developing pre-eclampsia and also diabetes type 2 after delivery. Women who are obese and diabetic 
are associated with an increase in circulation adipokines (Saucedo et al., 2011). Insulin resistance is 
one of the major metabolic disorders that is related to gestational diabetes.  
 
In obesity, there are high level of circulating cytokines which can lead into inflammation, metabolic 
syndrome.  Recently, studies have shown that the elevation of c-reactive protein and ADMA are a 
major factor contributing to this metabolic dysfunction in obesity. Additionally, another main factor is 
the infiltration of the endothelium by neutrophils which cause inflammation and hence increase high 
risk of pre-eclampsia development. This correlates with studies that have reported that pre-eclampsia 
is associated with high markers of endothelial inflammation (Innes & Wimsatt, 1999; Lorentzen et al., 
1998). It is therefore not surprising that individuals with higher BMI and are overweight have high 
levels of adipokines such as C-peptide and visfatin and therefore likely candidates for developing pre-
eclampsia. It has been reported in several studies that among the many features of pre-eclampsia, 
hyperinsulinamia is common (Martinez-Abundis, 1996). 
 
4.4 HIV and obesity 
 
Obese or overweight individuals  have been reported to have high levels of adipokines like insulin, c-
peptide, GIP and GLP-1 which suggest that HIV positive individuals have high incidence of insulin 
resistance, hence higher risk of developing hypertension. Additionally, pregnancy on its own is 
associated with some level of insulin resistance leading to diabetes mellitus, this suggest that HIV 
positive pregnant individuals have even higher risk of developing insulin resistance and if they are 
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obese/overweight, the risk even higher (Kaaja et al., 1999; Innes et al., 1999; Lorentzen et al., 1999). 
Additionally, high levels of adhesion markers have been reported in HIV positive cohorts, this means 
that inflammation is also high. 
 
 
4.5 HIV and pre-eclampsia 
 
In our study, we report no significant differences in the levels of c-peptide (p>0.05); ghrelin (p>0.05); 
glucagon (p>0.05) and PAI-1 groups (p>0.05) between HIV negative and positive groups, irrespective 
of non-pregnancy or type of pregnancy (pre-eclamptic or normotensive). On the other hand we show 
significant differences between HIV positive and negative groups for, GIP (p<0.001); GLP-1 
(p<0.05); insulin (p<0.05) and Visfatin (p<0.05) irrespective of non-pregnancy and type of pregnancy.  
 
A study done by Suy and associates found that women who are HIV positive and on anti-HIV 
treatment have more incidence of pre-eclampsia than women who are HIV negative. Moreover, the 
introduction of ARV treatment to be administered to all pregnant HIV positive women have led to a 
decrease in mortality and morbidity among HIV infected individuals (Suy et al., 2006). Additionally, 
it has also led to lower incidences of mother-to-child HIV transmission. Moreover, this has been a 
major achievement in the department of obstetrics and gynaecology because not only did it led to 
decrease in maternal mortality and mother-to-child HIV transmission, it also allowed women of fertile 
age, who are HIV positive with the chance to have babies who can be born without the virus.  
 
Sadly though, despite the positive effect of ARV’s in management of HIV infection, it has been 
reported that long term exposure to the anti-HIV treatment is reportedly associated with long term 
complications such as lipodystrophy and cardiovascular diseases (Martinez et al., 1999). Obstetric 
complications associated with fetal death are and not limited to preterm birth, low birthweight, 
intrauterine, growth retardation and may lead to fetal death if they are severe. Interestingly, Stratton 
and associates (1999), have reported that adverse pregnancy outcomes due to pre-eclampsia among 
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HIV positive individuals was a common problem before it was compulsory for all HIV positive 
women to take HAART but now it is not. Additionally, Wimmalasundera et al., (2002), have found 
high incidence of pre-eclampsia among HIV positive women, suggesting that HIV does not give 
immunity against pre-eclampsia. A short survey done by the European collaborative study in 2003, 
have further reported that they identify pre-eclampsia as one of the most common condition among 
HIV positive women but only those who are on the HARRT treatment. This was further supported by 
the study done by Suy and associates in 2003 who reported to have found high incidence in the 
number of cases of pre-eclampsia in HIV positive individuals on HAART. Additionally, they have 
also found incidence of fetal deaths to be high in individuals with pre-eclampsia and HIV positive. 
Pre-eclampsia and cases of fetal deaths was found to coexist more frequently among HIV positive 
individuals.  
 
In 2001, Martinez study have found that not only does HIV individuals on HAART have high risk of 
developing pre-eclampsia, they are also at risk of developing lipodystrophy and myocardial infection. 
Moreover, a systematic review on maternal infection and pre-eclampsia found no association between 
pre-eclampsia and HIV (Conde-Agudelo et al., 2008). Furthermore, another more recent study argue 
that women have high risk of developing pre-eclampsia only if they have been on HAART for a long 
time before pre-gnancy, additionally, have shown a strong association between pre-eclampsia and 
high BMI (Machado et al., 2014). Additionally, Suy and associates in 2006, reported that HAART 
increase risk of pre-eclampsia. However, a study done by Frank and associates to determine whether 
HIV positive women have lower rates of pre-eclampsia than HIV negative have found no reduction 











This study reports no significant difference in the levels of c-peptide (p>0.05); ghrelin (p>0.05); 
glucagon (p>0.05) and PAI-1 groups (p>0.05) between HIV negative and positive groups, irrespective 
of non-pregnant or type of pregnancy (pre-eclamptic or normotensive). On the other hand we show 
significant differences between HIV positive and negative groups for, GIP (p=0.00065); GLP-1 
(p=0.03); insulin (p>0.05) and Visfatin (p=0.0108) irrespective of non-pregnant and type of 
pregnancy . In terms of HIV status, we have observed that many of the adipokines were elevated in 
the HIV positive compared to the HIV negative group. These novel results implicates a role of HIV 
infection in the dysregulation of adipokines.  
 
We report that c-peptide, GIP, GLP-1 and glucagon differed between the non-pregnant and 
normotensive groups (p<0.05). There was no dysregulation of ghrelin and PAI-1 amongst non-
pregnant, normotensive pregnant and pre-eclamptic pregnancies (p>0.05). Additionally, c-peptide, 
GIP and GLP-1 differed between the normotensive and the late onset group respectively (p<0.05). 
Visfatin varied between the late onset versus the non-pregnant group and GIP between the 
normotensive versus early onset pre-eclamptic groups (p<0.05). 
 
These adipokines play a role in glucose homeostasis contribute to the development of insulin 
resistance, a high risk factor pre-eclampsia development. Additionally, elevated adipokines in 
individuals with high BMI (obese and overweight) predisposes one to pre-eclampsia development. 
 
 In conclusion, our study is the first to examine adipokine dysregulation in the triad of HIV infection, 
pre-eclampsia and obesity. Furthermore, we have established that adipokines: C-peptide, GIP, GLP-1, 
PAI-1 and visfatin were significantly dysregulated hence they may have predictor test value in 
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diagnosing pre-eclampsia development. Based on the results we conclude that c–peptide, visfatin and 
gastric inhibitory polypeptide may be used as biomarkers to predict pre-development. 
 
4.7 Limitations of the study 
 
These include: 
• Pre-pregnancy BMI- this was not available for all study participants. 
• Duration of anti-HIV therapy- were not available all HIV positive participants. 
• Family history with hypertension- most women were not able to contribute to this question. 
• Levels of adipokines at each trimester- these results would strengthen our findings 
• Adipokine levels post-partum adipokine levels for at least a short period postpartum would be 
of immense value. 
• HAART pregnancy correlate  adipokine levels with HIV management therapy 
• Viral load-in each trimester is required as pregnancy itself, may accelerates HIV replication 
and progression 
• Neonatal care- adherence to treatment is not known.   
 
4.8 Further direction 
 
We envisage further studies to compare levels of adipokines at each trimester as well as in HIV 
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